

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 August 2001 (02.08.2001)

PCT

(10) International Publication Number
WO 01/54498 A1

(51) International Patent Classification⁷: A01N 7/36, 41/06

(74) Agents: LLOYD, Jeff et al.; Saliwanchik, Lloyd & Saliwanchik, Suite A-1, 2421 N.W. 41st Street, Gainesville, FL 32606-6669 (US).

(21) International Application Number: PCT/US01/02871

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 29 January 2001 (29.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/179,005 28 January 2000 (28.01.2000) US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): AKKADIX CORPORATION [US/US]; 11099 North Torrey Pines, Suite 200, La Jolla, CA 92037 (US).

Published:


— with international search report

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): CHALQUEST, Richard, R. [US/US]; 7597 Eads Avenue, #C, La Jolla, CA 92037 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHODS USING SUBSTITUTED HYDROXYPROLINE DERIVATIVES FOR KILLING NEMATODES AND NEMATODE EGGS



(47)

(57) Abstract: Methods and compositions for the control of nematodes are disclosed. Specifically, substituted hydroxyproline anthelmintic compounds of formula (47) have been found to advantageously control nematodes at concentrations which are non-phytotoxic. The anthelmintic compounds can be used in conjunction with other nematicidal agents such as free fatty acids, fatty acid salts, avermectins, ivermectin, and milbemycin. R₁ is C₁₋₅ branched or straight alkyl (optionally substituted with phenyl); C₃₋₈ cyclic alkyl; aryl (optionally substituted with C₁₋₁₀ branched or straight alkyl, or OC₁₋₃); R₂ is C₁₋₅ branched or straight alkyl which is optionally substituted with aryl (optionally substituted OC₁₋₅ or OAr); NCH₂R₅ wherein R₅ is Ar (optionally substituted with OCF₃); OC₁₋₅, CH₂OR₆ wherein R₆ is C₁₋₅ alkyl or C₃₋₈ cyclic alkyl (optionally substituted with C₁₋₅ straight or branched alkyl, or OC₁₋₅); aryl (optionally substituted with C₁₋₅ straight or branched alkyl; OC₁₋₅; halogen; naphthyl (optionally substituted with OC₁₋₅ or an amine); or a 3 ring fused polycyclic group; R₃ is H; C₁₋₅ branched or straight alkyl which is optionally substituted with aryl (optionally substituted with halogen, OC₁₋₅, C₁₋₅ branched or straight alkyl); OC₁₋₅; C₂₋₈ ether; cyclic alkyl (optionally substituted with C₁₋₁₀ branched, straight, or cyclic alkyl); aryl (optionally substituted with halogen, C₁₋₅ straight or branched alkyl; OCF₃); R₄ is H, C₁₋₅ branched or straight alkyl which is optionally substituted with aryl (optionally substituted with halogen, OC₁₋₅, C₁₋₅ branched or straight alkyl; OC₁₋₅; C₂₋₈ ether; cyclic alkyl (optionally substituted with C₁₋₁₀ branched, straight, or cyclic alkyl); aryl (optionally substituted with halogen, C₁₋₅ straight or branched alkyl; OCF₃); and X is CO or SO₂.

WO 01/54498 A1

DESCRIPTIONMETHODS AND MATERIALS FOR KILLING NEMATODES
AND NEMATODE EGGS

5

Cross-Reference to a Related Application

This application claims the benefit of U.S. Provisional Application No. 60/179,005, filed January 28, 2000.

10

Background of the Invention

Nematodes are important plant pests which cause millions of dollars of damage each year to turf grasses, ornamental plants, and food crops. Efforts to eliminate or minimize damage caused by nematodes in agricultural settings have typically involved the use of soil fumigation with materials such as chloropicrin, methyl bromide, and dazomet, which volatilize to spread the active ingredient throughout the soil. Such fumigation materials can be highly toxic and may create an environmental hazard. Various non-fumigant chemicals have also been used, but these, too, create serious environmental problems and can be highly toxic to humans.

The accepted methodology for control of nematodes afflicting animals has centered around the use of the drug benzimidazole and its congeners. The use of these drugs on a wide scale has led to many instances of resistance among nematode populations (Prichard, R.K. *et al.* [1980] "The problem of anthelmintic resistance in nematodes," *Austr. Vet. J.* 56:239-251; Coles, G.C. [1986] "Anthelmintic resistance in sheep," In *Veterinary Clinics of North America: Food Animal Practice*, Vol 2:423-432 [Herd, R.P., Eds.] W.B. Saunders, New York).

The pesticidal activity of avermectins is well known. The avermectins are disaccharide derivatives of pentacyclic, 16-membered lactones. They can be divided into four major compounds: A_{1a}, A_{2a}, B_{1a}, and B_{2a}; and four minor compounds: A_{1b}, A_{2b}, B_{1b}, and B_{2b}.

The organism which produces avermectins was isolated and identified as *Streptomyces avermitilis* MA-4680 (NRRL-8165). Characteristics of the avermectin producing culture and the fermentation process are well documented and known to those

skilled in the art (Burg, R.W. *et al.* [1979] "Avermectins, New Family of Potent Anthelmintic Agents: Producing Organism and Fermentation," *Antimicrob. Agents Chemother.* 15(3):361-367). The isolation and purification of these compounds is also described in U.S. Patent No. 4,310,519 issued January 12, 1982.

5 Another family of pesticides produced by fermentation are the milbemycins, which are closely related to the avermectins. The milbemycins can be produced by a variety of *Streptomyces* and originally differed from the avermectins only in the C-13 position. The milbemycins and their many derivatives are also well known to those skilled in the art and are the subject of U.S. patents. See, for example, U.S. Patent No.
10 4,547,520.

While the avermectins were initially investigated for their anthelmintic activities, they were later found to have other insecticidal properties, although the degree varies. The activity of avermectins must generally be determined empirically.

22,23-dihydroavermectin B₁ is a synthetic derivative of the avermectins and has
15 been assigned the nonproprietary name of ivermectin. It is a mixture of 80% 22,23-dihydroavermectin B_{1a} and 20% 22,23-dihydroavermectin B_{1b}. Ivermectin has been tested on a variety of laboratory and domestic animals for control of nematodes, ticks, and heartworms.

Avermectin B_{2a} is active against the root-knot nematode, *Meloidogyne incognita*.
20 It is reported to be 10-30 times as potent as commercial contact nematicides when incorporated into soil at 0.16-0.25 kg/ha (Boyce Thompson Institute for Plant Research 58th Annual Report [1981]; Putter, I. *et al.* [1981] "Avermectins: Novel Insecticides, Acaracides, and Nematicides from a Soil Microorganism," *Experientia* 37:963-964). Avermectin B_{2a} is not toxic to tomatoes or cucumbers at rates of up to 10 kg/ha.
25 Avermectin B₁ is a combination of avermectin B_{1a} (major component) and avermectin B_{1b}. It has demonstrated a broad spectrum of insecticidal activities. The data indicate that avermectin B₁ is primarily a miticide, although it is also effective on the Colorado potato beetle, potato tuberworm, beet armyworm, diamondback moth, gypsy moth, and the European corn borer.

30 The use of avermectins in various agricultural applications has been described in publications and patents. The use of avermectin with spray oils (lightweight oil compositions) has been described. See, for example, U.S. Patent No. 4,560,677 issued

December 24, 1985; EPO applications 0 094 779 and 0 125 155; and Anderson, T.E., J.R. Babu, R.A. Dybas, H. Mehta (1986) *J. Econ. Entomol.* 79:197-201.

There is a continuing need for new, alternative materials and methods useful for killing nematodes.

5

Brief Summary of the Invention

The subject invention concerns substituted compositions and processes for controlling nematodes. In one embodiment, the subject invention comprises the use of certain substituted hydroxyproline compounds to control nematodes which infest and afflict animals. Nematodes which infest plants or the situs of plants can also be controlled using the methods and compositions of the subject invention, as can other acarid and arthropod pests.

Preferred compounds useful according to the subject invention can be represented by the Formulae I, II, III, IV, and V as further described herein.

1. A urea derivative of the following Formula I:



wherein Ar is aryl or heteroaryl optionally substituted by one or more R³ groups;

each Alk is a linear or cyclic alkylene radical of up to 8 C atoms;

R¹ is H or C₁₋₆ alkyl;

R² is heteroaryl or heterocycloalkyl optionally substituted by Ar, or forms such a group by cyclisation with R¹; and


R³ is OH, halogen, CF₃, OCF₃, or a group selected from NH₂, SO₂-C₁₋₆ alkyl, C₆₋₁₀ aryl, C₆₋₁₀ aryloxy, C₅₋₆ cycloalkyl, C₁₋₅ alkoxy, and C₁₋₆ alkyl, said group being optionally substituted by OH, C₁₋₆ alkoxy, C₁₋₆ alkyl, phenyl, halogen, or CF₃.

Particularly preferred anthelmintic compounds according to Formula I are exemplified herein by compounds represented by structures 1-10 (depicted in Figures 1-10, respectively), which have been assigned the respective reference numbers:

AKC 111 (STRUCTURE 1),
 AKC 112 (STRUCTURE 2),
 AKC 113 (STRUCTURE 3),
 AKC 107 (STRUCTURE 4),

- AKC 114 (STRUCTURE 5),
 AKC 108 (STRUCTURE 6),
 AKC 115 (STRUCTURE 7),
 AKC 116 (STRUCTURE 8),
 5 AKC 117 (STRUCTURE 9), and
 AKC 118 (STRUCTURE 10).

2. A heterocycle-substituted amide of the following Formula II:



- 10 wherein Ar is aryl or heteroaryl optionally substituted by one or more R^3 groups;
 each Alk is an optionally cyclic alkylene radical of up to 8 C atoms;
 Het is heteroaryl or heterocycloalkyl optionally substituted by Ar and/or R^3 ; and
 R^3 is OH, halogen, CF_3 , OCF_3 , or a group selected from NH_2 , SO_2 alkyl, C_{6-10} aryl,
 C_{1-6} alkoxy, and C_{1-6} alkyl, said group being optionally substituted by OH, C_{1-6} alkoxy,
 15 C_{1-6} alkyl, phenyl, halogen, or CF_3 .

Particularly preferred anthelmintic compounds according to Formula II are exemplified herein by compounds represented by structures 11-25 (depicted in Figures 11-25 respectively), which have been assigned the respective reference numbers:

- AKC 119 (STRUCTURE 11),
 20 AKC 110 (STRUCTURE 12),
 AKC 120 (STRUCTURE 13),
 AKC 121 (STRUCTURE 14),
 AKC 2153 (STRUCTURE 15),
 AKC 122 (STRUCTURE 16),
 25 AKC 104 (STRUCTURE 17),
 AKC 123 (STRUCTURE 18),
 AKC 124 (STRUCTURE 19),
 AKC 125 (STRUCTURE 20),
 AKC 105 (STRUCTURE 21),
 30 AKC 126 (STRUCTURE 22),
 AKC 102 (STRUCTURE 23),
 AKC 103 (STRUCTURE 24), and

AKC 171 (STRUCTURE 25).

3. A secondary arylamine of the following Formula III:

5
$$\text{Ar-NH-CHR-CH}_2\text{-CO-Y} \quad (\text{Formula III})$$

wherein Ar is aryl or heteroaryl optionally substituted by one or more R³ groups ;

R is aryl, heteroaryl, or heterocycloalkyl optionally substituted by R³ ;

Y is C₁₋₆ alkyl, aryl, or heteroaryl optionally substituted by R³ ;

or R and Y together form a cycloalkyl or heterocycloalkyl ring; and

10 R³ is OH, halogen, CF₃, OCF₃, or a group selected from NH₂, SO₂ alkyl, C₆₋₁₀ aryl, C₁₋₆ alkoxy, and C₁₋₆ alkyl, said group being optionally substituted by OH, C₁₋₆ alkoxy, C₁₋₆ alkyl, phenyl, halogen, or CF₃.

Particularly preferred anthelmintic compounds according to Formula III are exemplified herein by compounds represented by structures 26-31 (depicted in Figures

15 26-31, respectively), which have been assigned the respective reference numbers:

AKC 128 (STRUCTURE 26),

AKC 129 (STRUCTURE 27),

AKC 130 (STRUCTURE 28),

AKC 131 (STRUCTURE 29),

20 AKC 132 (STRUCTURE 30), and

AKC 133 (STRUCTURE 31).

4. A diaryl amine of the following Formula IV:

25
$$\text{Ar-(Z)}_{0-1}\text{-Ar-(CH}_2\text{)}_{0-1}\text{-NHR} \quad (\text{Formula IV})$$

wherein Ar is aryl or heteroaryl optionally substituted by one or more R³ groups;

Z is NH, O, S, or Alk; and Alk is a linear or cyclic alkylene radical of up to 8 C atoms

wherein said radical optionally includes one or more heteroatoms;

30 R is H or R³,

R³ is OH, halogen, CF₃, OCF₃, or a group selected from NH₂, SO₂ alkyl, C₆₋₁₀ aryl, C₁₋₆ alkoxy, and C₁₋₆ alkyl, said group being optionally substituted by OH, C₁₋₆ alkoxy, C₁₋₆ alkyl, phenyl, halogen, or CF₃.

Particularly preferred anthelmintic compounds according to Formula IV are
5 exemplified by compounds represented by structures 32-37 (depicted in Figures 32-37, respectively), which have been assigned the respective reference numbers:

AKC 109 (STRUCTURE 32),
AKC 134 (STRUCTURE 33),
AKC 135 (STRUCTURE 34),
10 AKC 136 (STRUCTURE 35),
AKC 137 (STRUCTURE 36), and
AKC 138 (STRUCTURE 37).

5. A substituted heteropolycyclic compound of the following Formula V:

15 Het₂-Q (Formula V)

wherein Het₂ is two or three fused aromatic rings including one or more heteroatoms selected from N, O and S, and Q includes at least one substituent selected from OH, COOR³ and CONHR³, and optionally also another substituent selected from alkyl and alkenyl of up to 10 C atoms;

20 wherein R³ is OH, halogen, CF₃, OCF₃, or a group selected from NH₂, SO₂ alkyl, C₆₋₁₀ aryl, C₁₋₆ alkoxy, and C₁₋₆ alkyl, said group being optionally substituted by OH, C₁₋₆ alkoxy, C₁₋₆ alkyl, phenyl, halogen, or CF₃.

Particularly preferred anthelmintic compounds according to Formula V are
exemplified by compounds represented by structures 38-43 (depicted in Figures 38-43,
25 respectively), which have been assigned the respective reference numbers:

AKC 139 (STRUCTURE 38),
AKC 140 (STRUCTURE 39),
AKC 141 (STRUCTURE 40),
AKC 142 (STRUCTURE 41),
30 AKC 143 (STRUCTURE 42), and
AKC 144 (STRUCTURE 43).

For the foregoing Formulae I, II, III, IV, and V, as well as throughout this disclosure, the following definitions apply.

"Aryl" refers to an aromatic group, typically of 6-10 C atoms, such as phenyl or naphthyl.

5 "Alk" includes, for example, $(CH_2)_n$ wherein n is an integer of up to 6, e.g. 1, 2, 3, or 4, or cyclohexylene.

"Heteroaryl" means an aromatic group including one or more heteroatoms selected from O, S and N. It will typically have 5 or 6 ring atoms. It may also be fused to one or more aryl groups. Examples are in the illustrated compounds.

10 "Heterocycloalkyl" means a cycloalkyl group in which one or more C atoms are replaced by one or more heteroatoms selected from O, S and N. It will typically have 5 or 6 ring atoms. Examples are in the illustrated compounds of structures 1-43.

Other preferred anthelmintic compounds useful according to the subject invention are represented by structures 44, 45, and 46 (depicted in Figures 44-46, respectively), and
15 have been assigned the respective reference numbers:

AKC 145	(STRUCTURE 44),
AKC 146	(STRUCTURE 45), and
AKC 147	(STRUCTURE 46).

20 The invention process is particularly valuable to control nematodes which are pests to animals, as well as nematodes attacking the roots of desired crop plants, ornamental plants, and turf grasses. The desired crop plants can be, for example, cotton, soybean, tomatoes, potatoes, grapes, strawberries, bananas, or vegetables.

In one embodiment of the subject invention, the subject anthelmintic compounds
25 are used in conjunction with one or more other nematicidal agents. The other nematicidal agents may be, for example, a biological agent, an avermectin, a milbemycin, or a fatty acid.

In another embodiment, the subject invention further provides methods for killing the eggs of nematodes. Thus, the subject invention further relates to the surprising
30 discovery that certain compounds have ovicidal activity against nematode eggs. Compositions comprising the anthelmintic compounds of the subject invention are particularly useful for preplant applications in nematode-control schemes.

Description of the Drawings

- Figure 1** depicts Structure 1 which represents anthelmintic compound AKC 111.
- Figure 2** depicts Structure 2 which represents anthelmintic compound AKC 112.
- Figure 3** depicts Structure 3 which represents anthelmintic compound AKC 113.
- 5 **Figure 4** depicts Structure 4 which represents anthelmintic compound AKC 107.
- Figure 5** depicts Structure 5 which represents anthelmintic compound AKC 114.
- Figure 6** depicts Structure 6 which represents anthelmintic compound AKC 108.
- Figure 7** depicts Structure 7 which represents anthelmintic compound AKC 115.
- Figure 8** depicts Structure 8 which represents anthelmintic compound AKC 116.
- 10 **Figure 9** depicts Structure 9 which represents anthelmintic compound AKC 117.
- Figure 10** depicts Structure 10 which represents anthelmintic compound AKC 118.
- Figure 11** depicts Structure 11 which represents anthelmintic compound AKC 119.
- 15 **Figure 12** depicts Structure 12 which represents anthelmintic compound AKC 110.
- Figure 13** depicts Structure 13 which represents anthelmintic compound AKC 120.
- Figure 14** depicts Structure 14 which represents anthelmintic compound AKC 121.
- 20 **Figure 15** depicts Structure 15 which represents anthelmintic compound AKC 2153.
- Figure 16** depicts Structure 16 which represents anthelmintic compound AKC 122.
- 25 **Figure 17** depicts Structure 17 which represents anthelmintic compound AKC 104.
- Figure 18** depicts Structure 18 which represents anthelmintic compound AKC 123.
- Figure 19** depicts Structure 19 which represents anthelmintic compound AKC 124.
- 30 **Figure 20** depicts Structure 20 which represents anthelmintic compound AKC 125.

105. **Figure 21** depicts Structure 21 which represents anthelmintic compound AKC
126. **Figure 22** depicts Structure 22 which represents anthelmintic compound AKC
- 5 102. **Figure 23** depicts Structure 23 which represents anthelmintic compound AKC
103. **Figure 24** depicts Structure 24 which represents anthelmintic compound AKC
- 10 171. **Figure 25** depicts Structure 25 which represents anthelmintic compound AKC
128. **Figure 26** depicts Structure 26 which represents anthelmintic compound AKC
129. **Figure 27** depicts Structure 27 which represents anthelmintic compound AKC
- 15 130. **Figure 28** depicts Structure 28 which represents anthelmintic compound AKC
121. **Figure 29** depicts Structure 29 which represents anthelmintic compound AKC
- 20 132. **Figure 30** depicts Structure 30 which represents anthelmintic compound AKC
133. **Figure 31** depicts Structure 31 which represents anthelmintic compound AKC
109. **Figure 32** depicts Structure 32 which represents anthelmintic compound AKC
- 25 134. **Figure 33** depicts Structure 33 which represents anthelmintic compound AKC
135. **Figure 34** depicts Structure 34 which represents anthelmintic compound AKC
- 30 136. **Figure 35** depicts Structure 35 which represents anthelmintic compound AKC
137. **Figure 36** depicts Structure 36 which represents anthelmintic compound AKC

Figure 37 depicts Structure 37 which represents anthelmintic compound AKC 138.

Figure 38 depicts Structure 38 which represents anthelmintic compound AKC 139.

5 **Figure 39** depicts Structure 39 which represents anthelmintic compound AKC 140.

Figure 40 depicts Structure 40 which represents anthelmintic compound AKC 141.

10 **Figure 41** depicts Structure 41 which represents anthelmintic compound AKC 142.

Figure 42 depicts Structure 42 which represents anthelmintic compound AKC 143.

Figure 43 depicts Structure 43 which represents anthelmintic compound AKC 144.

15 **Figure 44** depicts Structure 44 which represents anthelmintic compound AKC 145.

Figure 45 depicts Structure 45 which represents anthelmintic compound AKC 146.

20 **Figure 46** depicts Structure 46 which represents anthelmintic compound AKC 147.

Figure 47 depicts a basic structure, Structure 47, of a preferred class of anthelmintic compound.

Figure 48 depicts anthelmintic compound AKC 1297 of the class represented in Figure 47.

25 **Figure 49** depicts anthelmintic compound AKC 1299 of the class represented in Figure 47.

Figure 50 depicts anthelmintic compound AKC 1300 of the class represented in Figure 47.

30 **Figure 51** depicts anthelmintic compound AKC 1298 of the class represented in Figure 47.

Figure 52 depicts anthelmintic compound AKC 1301 of the class represented in Figure 47.

Figure 53 depicts anthelmintic compound AKC 1302 of the class represented in Figure 47.

Figure 54 depicts anthelmintic compound AKC 126 of the class represented in Figure 47.

5 **Figure 55** depicts anthelmintic compound AKC 1303 of the class represented in Figure 47.

Figure 56 depicts anthelmintic compound AKC 1314 of the class represented in Figure 47.

10 **Figure 57** depicts anthelmintic compound AKC 1305 of the class represented in Figure 47.

Figure 58 depicts anthelmintic compound AKC 1315 of the class represented in Figure 47.

Figure 59 depicts anthelmintic compound AKC 1306 of the class represented in Figure 47.

15 **Figure 60** depicts anthelmintic compound AKC 1316 of the class represented in Figure 47.

Figure 61 depicts anthelmintic compound AKC 1307 of the class represented in Figure 47.

20 **Figure 62** depicts anthelmintic compound AKC 1317 of the class represented in Figure 47.

Figure 63 depicts anthelmintic compound AKC 1308 of the class represented in Figure 47.

Figure 64 depicts anthelmintic compound AKC 1318 of the class represented in Figure 47.

25 **Figure 65** depicts anthelmintic compound AKC 1304 of the class represented in Figure 47.

Figure 66 depicts anthelmintic compound AKC 1309 of the class represented in Figure 47.

30 **Figure 67** depicts anthelmintic compound AKC 102 of the class represented in Figure 47.

Figure 68 depicts anthelmintic compound AKC 1313 of the class represented in Figure 47.

Figure 69 depicts anthelmintic compound AKC 1319 of the class represented in Figure 47.

Figure 70 depicts anthelmintic compound AKC 1310 of the class represented in Figure 47.

5 **Figure 71** depicts anthelmintic compound AKC 1320 of the class represented in Figure 47.

Figure 72 depicts anthelmintic compound AKC 1311 of the class represented in Figure 47.

10 **Figure 73** depicts anthelmintic compound AKC 1321 of the class represented in Figure 47.

Figure 74 depicts anthelmintic compound AKC 1312 of the class represented in Figure 47.

Figure 75 depicts anthelmintic compound AKC 1322 of the class represented in Figure 47.

15 **Figure 76** depicts anthelmintic compound AKC 1323 of the class represented in Figure 47.

Figure 77 depicts anthelmintic compound AKC 1326 of the class represented in Figure 47.

20 **Figure 78** depicts anthelmintic compound AKC 1324 of the class represented in Figure 47.

Figure 79 depicts anthelmintic compound AKC 1327 of the class represented in Figure 47.

Figure 80 depicts anthelmintic compound AKC 1325 of the class represented in Figure 47.

25 **Figure 81** depicts anthelmintic compound AKC 1328 of the class represented in Figure 47.

Figure 82 depicts anthelmintic compound AKC 1331 of the class represented in Figure 47.

30 **Figure 83** depicts anthelmintic compound AKC 1329 of the class represented in Figure 47.

Figure 84 depicts anthelmintic compound AKC 1330 of the class represented in Figure 47.

Figure 85 depicts anthelmintic compound AKC 1332 of the class represented in Figure 47.

Figure 86 depicts anthelmintic compound AKC 1333 of the class represented in Figure 47.

5 **Figure 87** depicts anthelmintic compound AKC 1334 of the class represented in Figure 47.

Figure 88 depicts anthelmintic compound AKC 1335 of the class represented in Figure 47.

10 **Figure 89** depicts anthelmintic compound AKC 1337 of the class represented in Figure 47.

Figure 90 depicts anthelmintic compound AKC 1336 of the class represented in Figure 47.

Figure 91 depicts anthelmintic compound AKC 1339 of the class represented in Figure 47.

15 **Figure 92** depicts anthelmintic compound AKC 1345 of the class represented in Figure 47.

Figure 93 depicts anthelmintic compound AKC 1340 of the class represented in Figure 47.

20 **Figure 94** depicts anthelmintic compound AKC 1346 of the class represented in Figure 47.

Figure 95 depicts anthelmintic compound AKC 1338 of the class represented in Figure 47.

Figure 96 depicts anthelmintic compound AKC 1341 of the class represented in Figure 47.

25 **Figure 97** depicts anthelmintic compound AKC 1342 of the class represented in Figure 47.

Figure 98 depicts anthelmintic compound AKC 1347 of the class represented in Figure 47.

30 **Figure 99** depicts anthelmintic compound AKC 1343 of the class represented in Figure 47.

Figure 100 depicts anthelmintic compound AKC 1348 of the class represented in Figure 47.

Figure 101 depicts anthelmintic compound AKC 1344 of the class represented in Figure 47.

Figure 102 depicts anthelmintic compound AKC 1349 of the class represented in Figure 47.

5 **Figure 103** depicts anthelmintic compound AKC 1353 of the class represented in Figure 47.

Figure 104 depicts anthelmintic compound AKC 1350 of the class represented in Figure 47.

10 **Figure 105** depicts anthelmintic compound AKC 1351 of the class represented in Figure 47.

Figure 106 depicts anthelmintic compound AKC 1352 of the class represented in Figure 47.

Figure 107 depicts anthelmintic compound AKC 1354 of the class represented in Figure 47.

15 **Figure 108** depicts anthelmintic compound AKC 1355 of the class represented in Figure 47.

Figure 109 depicts anthelmintic compound AKC 1356 of the class represented in Figure 47.

20 **Figure 110** depicts anthelmintic compound AKC 1357 of the class represented in Figure 47.

Figure 111 depicts anthelmintic compound AKC 1358 of the class represented in Figure 47.

Figure 112 depicts anthelmintic compound AKC 1359 of the class represented in Figure 47.

25 **Figure 113** depicts anthelmintic compound AKC 1360 of the class represented in Figure 47.

Figure 114 depicts anthelmintic compound AKC 1368 of the class represented in Figure 47.

30 **Figure 115** depicts anthelmintic compound AKC 1361 of the class represented in Figure 47.

Figure 116 depicts anthelmintic compound AKC 1369 of the class represented in Figure 47.

Figure 117 depicts anthelmintic compound AKC 1362 of the class represented in Figure 47.

Figure 118 depicts anthelmintic compound AKC 1363 of the class represented in Figure 47.

5 **Figure 119** depicts anthelmintic compound AKC 1364 of the class represented in Figure 47.

Figure 120 depicts anthelmintic compound AKC 1365 of the class represented in Figure 47.

10 **Figure 121** depicts anthelmintic compound AKC 1366 of the class represented in Figure 47.

Figure 122 depicts anthelmintic compound AKC 1367 of the class represented in Figure 47.

Figure 123 depicts anthelmintic compound AKC 1377 of the class represented in Figure 47.

15 **Figure 124** depicts anthelmintic compound AKC 1370 of the class represented in Figure 47.

Figure 125 depicts anthelmintic compound AKC 1378 of the class represented in Figure 47.

20 **Figure 126** depicts anthelmintic compound AKC 1371 of the class represented in Figure 47.

Figure 127 depicts anthelmintic compound AKC 1372 of the class represented in Figure 47.

Figure 128 depicts anthelmintic compound AKC 1379 of the class represented in Figure 47.

25 **Figure 129** depicts anthelmintic compound AKC 1373 of the class represented in Figure 47.

Figure 130 depicts anthelmintic compound AKC 1380 of the class represented in Figure 47.

30 **Figure 131** depicts anthelmintic compound AKC 1374 of the class represented in Figure 47.

Figure 132 depicts anthelmintic compound AKC 1375 of the class represented in Figure 47.

Figure 133 depicts anthelmintic compound AKC 1381 of the class represented in Figure 47.

Figure 134 depicts anthelmintic compound AKC 1376 of the class represented in Figure 47.

5 **Figure 135** depicts anthelmintic compound AKC 1382 of the class represented in Figure 47.

Figure 136 depicts anthelmintic compound AKC 1390 of the class represented in Figure 47.

10 **Figure 137** depicts anthelmintic compound AKC 1383 of the class represented in Figure 47.

Figure 138 depicts anthelmintic compound AKC 1384 of the class represented in Figure 47.

Figure 139 depicts anthelmintic compound AKC 1391 of the class represented in Figure 47.

15 **Figure 140** depicts anthelmintic compound AKC 1385 of the class represented in Figure 47.

Figure 141 depicts anthelmintic compound AKC 1392 of the class represented in Figure 47.

20 **Figure 142** depicts anthelmintic compound AKC 1386 of the class represented in Figure 47.

Figure 143 depicts anthelmintic compound AKC 1393 of the class represented in Figure 47.

Figure 144 depicts anthelmintic compound AKC 1387 of the class represented in Figure 47.

25 **Figure 145** depicts anthelmintic compound AKC 1388 of the class represented in Figure 47.

Figure 146 depicts anthelmintic compound AKC 1394 of the class represented in Figure 47.

30 **Figure 147** depicts anthelmintic compound AKC 1389 of the class represented in Figure 47.

Figure 148 depicts anthelmintic compound AKC 1395 of the class represented in Figure 47.

Figure 149 depicts anthelmintic compound AKC 1396 of the class represented in Figure 47.

Figure 150 depicts anthelmintic compound AKC 1397 of the class represented in Figure 47.

5 **Figure 151** depicts anthelmintic compound AKC 1259 of the class represented in Figure 47.

Figure 152 depicts anthelmintic compound AKC 1260 of the class represented in Figure 47.

10 **Figure 153** depicts anthelmintic compound AKC 1261 of the class represented in Figure 47.

Figure 154 depicts anthelmintic compound AKC 1262 of the class represented in Figure 47.

Figure 155 depicts anthelmintic compound AKC 1268 of the class represented in Figure 47.

15 **Figure 156** depicts anthelmintic compound AKC 1263 of the class represented in Figure 47.

Figure 157 depicts anthelmintic compound AKC 1267 of the class represented in Figure 47.

20 **Figure 158** depicts anthelmintic compound AKC 1269 of the class represented in Figure 47.

Figure 159 depicts anthelmintic compound AKC 1264 of the class represented in Figure 47.

Figure 160 depicts anthelmintic compound AKC 1270 of the class represented in Figure 47.

25 **Figure 161** depicts anthelmintic compound AKC 1265 of the class represented in Figure 47.

Figure 162 depicts anthelmintic compound AKC 1271 of the class represented in Figure 47.

30 **Figure 163** depicts anthelmintic compound AKC 1266 of the class represented in Figure 47.

Figure 164 depicts anthelmintic compound AKC 1406 of the class represented in Figure 47.

Figure 165 depicts anthelmintic compound AKC 1398 of the class represented in Figure 47.

Figure 166 depicts anthelmintic compound AKC 1407 of the class represented in Figure 47.

5 **Figure 167** depicts anthelmintic compound AKC 1399 of the class represented in Figure 47.

Figure 168 depicts anthelmintic compound AKC 1408 of the class represented in Figure 47.

10 **Figure 169** depicts anthelmintic compound AKC 1400 of the class represented in Figure 47.

Figure 170 depicts anthelmintic compound AKC 1409 of the class represented in Figure 47.

Figure 171 depicts anthelmintic compound AKC 1401 of the class represented in Figure 47.

15 **Figure 172** depicts anthelmintic compound AKC 1410 of the class represented in Figure 47.

Figure 173 depicts anthelmintic compound AKC 1402 of the class represented in Figure 47.

20 **Figure 174** depicts anthelmintic compound AKC 1411 of the class represented in Figure 47.

Figure 175 depicts anthelmintic compound AKC 1403 of the class represented in Figure 47.

Figure 176 depicts anthelmintic compound AKC 1412 of the class represented in Figure 47.

25 **Figure 177** depicts anthelmintic compound AKC 1404 of the class represented in Figure 47.

Figure 178 depicts anthelmintic compound AKC 1413 of the class represented in Figure 47.

30 **Figure 179** depicts anthelmintic compound AKC 1405 of the class represented in Figure 47.

Figure 180 depicts anthelmintic compound AKC 1422 of the class represented in Figure 47.

Figure 181 depicts anthelmintic compound AKC 1414 of the class represented in Figure 47.

Figure 182 depicts anthelmintic compound AKC 1423 of the class represented in Figure 47.

5 **Figure 183** depicts anthelmintic compound AKC 1415 of the class represented in Figure 47.

Figure 184 depicts anthelmintic compound AKC 1424 of the class represented in Figure 47.

10 **Figure 185** depicts anthelmintic compound AKC 1416 of the class represented in Figure 47.

Figure 186 depicts anthelmintic compound AKC 1425 of the class represented in Figure 47.

Figure 187 depicts anthelmintic compound AKC 1417 of the class represented in Figure 47.

15 **Figure 188** depicts anthelmintic compound AKC 1418 of the class represented in Figure 47.

Figure 189 depicts anthelmintic compound AKC 1426 of the class represented in Figure 47.

20 **Figure 190** depicts anthelmintic compound AKC 1419 of the class represented in Figure 47.

Figure 191 depicts anthelmintic compound AKC 1427 of the class represented in Figure 47.

Figure 192 depicts anthelmintic compound AKC 1420 of the class represented in Figure 47.

25 **Figure 193** depicts anthelmintic compound AKC 1428 of the class represented in Figure 47.

Figure 194 depicts anthelmintic compound AKC 1421 of the class represented in Figure 47.

30 **Figure 195** depicts anthelmintic compound AKC 1437 of the class represented in Figure 47.

Figure 196 depicts anthelmintic compound AKC 1429 of the class represented in Figure 47.

Figure 197 depicts anthelmintic compound AKC 1438 of the class represented in Figure 47.

Figure 198 depicts anthelmintic compound AKC 1430 of the class represented in Figure 47.

5 **Figure 199** depicts anthelmintic compound AKC 1439 of the class represented in Figure 47.

Figure 200 depicts anthelmintic compound AKC 1431 of the class represented in Figure 47.

10 **Figure 201** depicts anthelmintic compound AKC 1440 of the class represented in Figure 47.

Figure 202 depicts anthelmintic compound AKC 1432 of the class represented in Figure 47.

Figure 203 depicts anthelmintic compound AKC 1441 of the class represented in Figure 47.

15 **Figure 204** depicts anthelmintic compound AKC 1433 of the class represented in Figure 47.

Figure 205 depicts anthelmintic compound AKC 1442 of the class represented in Figure 47.

20 **Figure 206** depicts anthelmintic compound AKC 1434 of the class represented in Figure 47.

Figure 207 depicts anthelmintic compound AKC 1443 of the class represented in Figure 47.

Figure 208 depicts anthelmintic compound AKC 1435 of the class represented in Figure 47.

25 **Figure 209** depicts anthelmintic compound AKC 1444 of the class represented in Figure 47.

Figure 210 depicts anthelmintic compound AKC 1436 of the class represented in Figure 47.

30 **Figure 211** depicts anthelmintic compound AKC 1445 of the class represented in Figure 47.

Figure 212 depicts anthelmintic compound AKC 1446 of the class represented in Figure 47.

Figure 213 depicts anthelmintic compound AKC 1272 of the class represented in Figure 47.

Figure 214 depicts anthelmintic compound AKC 1273 of the class represented in Figure 47.

5 **Figure 215** depicts anthelmintic compound AKC 1274 of the class represented in Figure 47.

Figure 216 depicts anthelmintic compound AKC 1275 of the class represented in Figure 47.

10 **Figure 217** depicts anthelmintic compound AKC 1276 of the class represented in Figure 47.

Figure 218 depicts anthelmintic compound AKC 1280 of the class represented in Figure 47.

Figure 219 depicts anthelmintic compound AKC 1277 of the class represented in Figure 47.

15 **Figure 220** depicts anthelmintic compound AKC 1278 of the class represented in Figure 47.

Figure 221 depicts anthelmintic compound AKC 1279 of the class represented in Figure 47.

20 **Figure 222** depicts anthelmintic compound AKC 1455 of the class represented in Figure 47.

Figure 223 depicts anthelmintic compound AKC 1447 of the class represented in Figure 47.

Figure 224 depicts anthelmintic compound AKC 1456 of the class represented in Figure 47.

25 **Figure 225** depicts anthelmintic compound AKC 1457 of the class represented in Figure 47.

Figure 226 depicts anthelmintic compound AKC 1448 of the class represented in Figure 47.

30 **Figure 227** depicts anthelmintic compound AKC 1458 of the class represented in Figure 47.

Figure 228 depicts anthelmintic compound AKC 1449 of the class represented in Figure 47.

Figure 229 depicts anthelmintic compound AKC 1459 of the class represented in Figure 47.

Figure 230 depicts anthelmintic compound AKC 1450 of the class represented in Figure 47.

5 **Figure 231** depicts anthelmintic compound AKC 1454 of the class represented in Figure 47.

Figure 232 depicts anthelmintic compound AKC 1460 of the class represented in Figure 47.

10 **Figure 233** depicts anthelmintic compound AKC 1451 of the class represented in Figure 47.

Figure 234 depicts anthelmintic compound AKC 1461 of the class represented in Figure 47.

Figure 235 depicts anthelmintic compound AKC 1452 of the class represented in Figure 47.

15 **Figure 236** depicts anthelmintic compound AKC 1453 of the class represented in Figure 47.

Figure 237 depicts anthelmintic compound AKC 1469 of the class represented in Figure 47.

20 **Figure 238** depicts anthelmintic compound AKC 1462 of the class represented in Figure 47.

Figure 239 depicts anthelmintic compound AKC 1470 of the class represented in Figure 47.

Figure 240 depicts anthelmintic compound AKC 1463 of the class represented in Figure 47.

25 **Figure 241** depicts anthelmintic compound AKC 1471 of the class represented in Figure 47.

Figure 242 depicts anthelmintic compound AKC 1464 of the class represented in Figure 47.

30 **Figure 243** depicts anthelmintic compound AKC 1472 of the class represented in Figure 47.

Figure 244 depicts anthelmintic compound AKC 1465 of the class represented in Figure 47.

Figure 245 depicts anthelmintic compound AKC 1466 of the class represented in Figure 47.

Figure 246 depicts anthelmintic compound AKC 1473 of the class represented in Figure 47.

5 **Figure 247** depicts anthelmintic compound AKC 1467 of the class represented in Figure 47.

Figure 248 depicts anthelmintic compound AKC 1474 of the class represented in Figure 47.

10 **Figure 249** depicts anthelmintic compound AKC 1468 of the class represented in Figure 47.

Figure 250 depicts anthelmintic compound AKC 1475 of the class represented in Figure 47.

Figure 251 depicts anthelmintic compound AKC 1486 of the class represented in Figure 47.

15 **Figure 252** depicts anthelmintic compound AKC 1478 of the class represented in Figure 47.

Figure 253 depicts anthelmintic compound AKC 1487 of the class represented in Figure 47.

20 **Figure 254** depicts anthelmintic compound AKC 1479 of the class represented in Figure 47.

Figure 255 depicts anthelmintic compound AKC 1488 of the class represented in Figure 47.

Figure 256 depicts anthelmintic compound AKC 1480 of the class represented in Figure 47.

25 **Figure 257** depicts anthelmintic compound AKC 1489 of the class represented in Figure 47.

Figure 258 depicts anthelmintic compound AKC 1476 of the class represented in Figure 47.

30 **Figure 259** depicts anthelmintic compound AKC 1477 of the class represented in Figure 47.

Figure 260 depicts anthelmintic compound AKC 1481 of the class represented in Figure 47.

Figure 261 depicts anthelmintic compound AKC 1490 of the class represented in Figure 47.

Figure 262 depicts anthelmintic compound AKC 1482 of the class represented in Figure 47.

5 **Figure 263** depicts anthelmintic compound AKC 1491 of the class represented in Figure 47.

Figure 264 depicts anthelmintic compound AKC 1483 of the class represented in Figure 47.

10 **Figure 265** depicts anthelmintic compound AKC 1492 of the class represented in Figure 47.

Figure 266 depicts anthelmintic compound AKC 1484 of the class represented in Figure 47.

Figure 267 depicts anthelmintic compound AKC 1493 of the class represented in Figure 47.

15 **Figure 268** depicts anthelmintic compound AKC 1485 of the class represented in Figure 47.

Figure 269 depicts anthelmintic compound AKC 1494 of the class represented in Figure 47.

20 **Figure 270** depicts anthelmintic compound AKC 1495 of the class represented in Figure 47.

Figure 271 depicts anthelmintic compound AKC 1496 of the class represented in Figure 47.

Figure 272 depicts anthelmintic compound AKC 1497 of the class represented in Figure 47.

25 **Figure 273** depicts anthelmintic compound AKC 1281 of the class represented in Figure 47.

Figure 274 depicts anthelmintic compound AKC 1282 of the class represented in Figure 47.

30 **Figure 275** depicts anthelmintic compound AKC 1283 of the class represented in Figure 47.

Figure 276 depicts anthelmintic compound AKC 1289 of the class represented in Figure 47.

Figure 277 depicts anthelmintic compound AKC 1284 of the class represented in Figure 47.

Figure 278 depicts anthelmintic compound AKC 1290 of the class represented in Figure 47.

5 **Figure 279** depicts anthelmintic compound AKC 1285 of the class represented in Figure 47.

Figure 280 depicts anthelmintic compound AKC 1286 of the class represented in Figure 47.

10 **Figure 281** depicts anthelmintic compound AKC 1287 of the class represented in Figure 47.

Figure 282 depicts anthelmintic compound AKC 1291 of the class represented in Figure 47.

Figure 283 depicts anthelmintic compound AKC 1288 of the class represented in Figure 47.

15 **Figure 284** depicts anthelmintic compound AKC 1498 of the class represented in Figure 47.

Figure 285 depicts anthelmintic compound AKC 1499 of the class represented in Figure 47.

20 **Figure 286** depicts anthelmintic compound AKC 1292 of the class represented in Figure 47.

Figure 287 depicts anthelmintic compound AKC 1296 of the class represented in Figure 47.

Figure 288 depicts anthelmintic compound AKC 1293 of the class represented in Figure 47.

25 **Figure 289** depicts anthelmintic compound AKC 1294 of the class represented in Figure 47.

Figure 290 depicts anthelmintic compound AKC 1295 of the class represented in Figure 47.

30 **Figure 291** depicts one library scheme by which the skilled artisan can create the compounds represented by the structure depicted in Figure 47.

Figure 292 depicts Scaffold 1.

Figure 293 depicts Scaffold 2.

Figure 294 depicts Scaffold 3.

Figure 295 depicts Scaffold 4.

Figure 296 depicts Scaffold 5.

Figure 297 depicts Scaffold 6.

5 Figure 298 depicts a preferred pathway for synthesis of hydroxyproline derivatives.

Figure 299 depicts a preferred alternate pathway for synthesis of hydroxyproline derivatives.

10 Figure 300 depicts a synthetic pathway using diamines on nitrophenol carbonate linker.

Figure 301 compares the original base structure of intended compounds with the preferred base structure of the subject compounds.

Detailed Disclosure of the Invention

15 The process of the subject invention concerns the use of certain organic compounds to control the infestation of plants or animals by nematodes. These organic compounds comprise Formulae I, II, III, IV, and V, as well as Structures 44, 45, and 46. In a particularly preferred embodiment of the subject invention, the anthelmintic compound is selected from the group consisting of Compounds 1-46 represented by
20 Structures 1-46. Particularly preferred are the compounds represented by Structures 22 and 23, and compounds related thereto as represented by Structure 47 depicted in Figure 47, and as further exemplified by Structures 48-290 depicted in Figures 48 through 290. Preferred anthelmintic compounds useful in accord with the subject invention are represented by Structure 47, wherein:

25 R_1 is C_{1-5} branched or straight alkyl (optionally substituted with phenyl); C_{3-8} cyclic alkyl; aryl (optionally substituted with C_{1-10} branched or straight alkyl, or OC_{1-5});

30 R_2 is C_{1-5} branched or straight alkyl which is optionally substituted with aryl (optionally substituted with OC_{1-5} or OAr); NCH_2R_5 wherein R_5 is Ar (optionally substituted with OCF_3); OC_{1-5} ; CH_2OR_6 wherein R_6 is C_{1-5} alkyl or C_{3-8} cyclic alkyl (optionally substituted with C_{1-5} straight or branched alkyl, or OC_{1-5}); aryl (optionally substituted with C_{1-5} straight or branched alkyl; OC_{1-5} ; halogen; naphthyl (optionally substituted with OC_{1-5} or an amine); or a 3 ring fused polycyclic group;

R_3 is H; C_{1-5} branched or straight alkyl which is optionally substituted with aryl (optionally substituted with halogen, OC_{1-5} , C_{1-5} branched or straight alkyl); OC_{1-5} ; C_{2-8} ether; cyclic alkyl (optionally substituted with C_{1-10} branched, straight, or cyclic alkyl); aryl (optionally substituted with halogen, C_{1-5} straight or branched alkyl, OCF_3);

5 R_4 is H; C_{1-5} branched or straight alkyl which is optionally substituted with aryl (optionally substituted with halogen, OC_{1-5} , C_{1-5} branched or straight alkyl); OC_{1-5} ; C_{2-8} ether; cyclic alkyl (optionally substituted with C_{1-10} branched, straight, or cyclic alkyl); aryl (optionally substituted with halogen, C_{1-5} straight or branched alkyl, OCF_3); and

X is CO or SO_2 .

10 Generally, the anthelmintic compounds of the subject invention can be unsubstituted or substituted, saturated or unsaturated. The anthelmintic component of an anthelmintic compounds used according to the subject invention may be a single anthelmintic compound or a mixture of two or more anthelmintic compounds. The subject compounds may be used in conjunction with other anthelmintic compounds,
15 including the free acids and salts of the anthelmintic compounds of the present invention. The salts may be, for example, sodium or potassium salts, or ammonium salts. As would be apparent to the ordinary skilled artisan, physiologically acceptable acids and salts of the subject anthelmintic compounds can readily be made and used in accord with the teachings herein, and are hereby expressly included by reference to each compound or
20 group of compounds. For example, "AKC 1297", "Compound 48", or "Structure 48" each refer to the same compounds and each is intended to include the physiologically acceptable acids and salts thereof. In addition, the subject anthelmintic compounds may have an asymmetrical carbon atom, *i.e.*, optically active site. These compounds exist in (R) and (S) enantiomeric forms. Both the (R) and (S) enantiomers of the subject
25 compounds are contemplated by the subject invention.

Anthelmintic compounds specifically exemplified herein include Compounds 1-46 represented by Structures 1-46 above, and Compounds 48-290 represented by Structures 48-290 depicted in Figures 48-290.

The subject compounds used in the invention can be applied to animals, the living
30 and feeding areas of animals, plants, or to the situs of plants needing nematode control. The anthelmintic compositions may be applied by, for example, drip and drench techniques. With the drip application, the subject compositions can be applied directly

to the base of plants or to the soil root zone. The composition may be applied through already existing drip irrigation systems. This procedure is particularly applicable for ornamental plants, strawberries, tomatoes, potatoes, grapes, and vegetables. Alternatively, a drench application can be used. For treating plants, a sufficient quantity
5 of the anthelmintic composition is applied such that the composition drains to the root area of the plants. An important aspect of the subject invention is the surprising discovery that certain compounds have excellent nematicidal activity at concentrations which are not phytotoxic.

The drench technique can be used for a variety of crops and for turf grasses. The
10 drench technique can also be used for animals. Preferably, for administration to animals the anthelmintic composition would be administered orally to facilitate activity against internal nematode parasites. The compositions of the subject invention can readily be applied using the teachings provided herein.

In a preferred embodiment of the subject invention, an anthelmintic compound
15 will be applied as an aqueous microemulsion. As described herein, the concentration of the active ingredient should be sufficient to control the nematode infestation without causing phytotoxicity to the desired plants. The concentration of anthelmintic compound may be, for example, from about 0.0001% to about 2%, preferably from about 0.025% to about 1%, and, most preferably, from about 0.05% to about 0.5%.

20 The anthelmintic composition used according to the subject invention can be applied in conjunction with one or more other nematicidal agents. The other nematicidal agent may, for example, be applied simultaneously or sequentially with the anthelmintic. Such other nematicidal agents include, for example, avermectins, the *B.t.s.*, and fatty acids.

25 The avermectin compound used according to the subject invention may be any of the avermectins, milbemycins, or derivatives of either, having activity against nematodes. The avermectin's activity will be enhanced when combined with an anthelmintic compound as described herein. Thus, the specific combination of ingredients can be manipulated to provide the optimal composition for a particular
30 application.

Standard concentrations of avermectins are well known to those skilled in the art. For example, the avermectin compounds can be employed in the combination of the

subject invention at concentrations of from about 0.03 to about 110 parts per million (ppm). Preferably, from about 1 to about 5 ppm are employed.

As would be readily appreciated by a person skilled in the art, the delivery of the subject anthelmintic and/or avermectin compound can be calculated in terms of the active ingredient applied per unit area. For example, the subject anthelmintic may be applied at a rate of about 0.02 lb/acre to about 0.1 lb/acre and, preferably, from about 0.5 lb/acre to about 2 lbs/acre. Similarly, the avermectin product can be applied at a rate of up to about 16 oz. of formulated product ("AVID," available from Merck) per acre. Preferably, about 4 oz. to about 8 oz. formulated "AVID" per acre would be used. Thus, the avermectin compound can be applied up to about 0.02 lb/acre. Preferably, the rate of avermectin is between about 0.005 lb/acre and 0.01 lb/acre. A person of ordinary skill in the art would readily appreciate that the desired application rate of the active ingredients could be achieved using a great variety of different concentrations of active ingredients while varying the application rate of the solution. Thus, a large quantity of dilute solution could be applied or a smaller quantity of a more concentrated solution.

A variety of different avermectins or related compounds can be used according to the subject invention. Ivermectin may also be used according to the subject invention, as may the milbemycins. For brevity, the term "avermectin" is used herein to refer to all the avermectins and their derivatives as well as related compounds such as the milbemycins and the ivermectins. "Derivatives" refer to chemical modifications of the avermectins or milbemycins which are well known and available to those skilled in this art. Such derivatives are described, for example, in U.S. Patent No. 4,560,677. Avermectin is readily available under a variety of tradenames including "AVID," "ZEPHYR," "VERTIMEC," and "AGRI-MEK."

The anthelmintic compositions of the subject invention may also be used in conjunction with nematicidal agents other than the avermectins. For example, the anthelmintic compounds may be used with biological agents such as *Bacillus thuringiensis* or with nematicidal fungi. In this context, the anthelmintic composition could be applied at concentrations which would not antagonize the action of the biological agent. The biologically active agent may be in a live proliferative form or may be in a dead stabilized form as described, for example, in U.S. Patent Nos. 4,695,462 and 4,695,455. Furthermore, the anthelmintic compositions of the subject invention may be

used with plants which are specifically bred or engineered for nematode resistance. The plants may, for example, be transformed with *B.t.* genes which confer nematode resistance or may simply be hybrids or varieties selected for such resistance. The anthelmintic compositions of the subject invention are particularly effective against free-living ectoparasitic nematodes and, therefore, combined use with plants selected for endoparasitic nematode resistance is highly advantageous.

The subject invention further relates to the surprising discovery that the anthelmintics of the subject invention have ovicidal activity against nematode eggs. Thus, in another embodiment, provided are methods for killing the eggs of nematodes, including those within cysts or egg masses that are commonly formed by *Heterodera*, *Globodera*, and *Meloidogyne* (cyst and root-knot) species.

The ovicidal compositions according to the subject invention are particularly useful for preplant applications in nematode-control schemes. In addition, the ovicidal compositions of the subject invention can be advantageously used as postplant nematicides, especially because of their relatively low phytotoxicity. In the latter embodiments, ovicidal compositions of the subject invention can be delivered, after planting and at appropriate, essentially non-phytotoxic concentrations of anthelmintic compounds, along with irrigation water and/or plant nutrients to ensure a continuous zone of nematode protection to the enlarging plant root mass. Thus, when applied using these techniques, which include drench or drip systems as are known in the art, phytopathogenic nematodes in their vermiform (wormlike) and egg stages are controlled.

Anthelmintic compounds having Formulae I, II, III, IV, and V, Structure 47, and most preferably Structures 1-46, and particularly Structures 22, 23 and Structures 48-290, are used in preferred embodiments for killing nematode eggs. In addition, microemulsions of the subject compounds are highly preferred for ovicidal applications. In preferred embodiments, the anthelmintic compound(s) will be present in a concentration of greater than about 150 ppm. More preferably, the concentration will be greater than about 200 ppm; most preferably it will be about 250 ppm or more. For certain conditions, the anthelmintic compounds should be applied at high concentrations of about 1,000 ppm to about 5,000 ppm or more.

In light of the subject disclosure, one skilled in the art could readily use a variety of application techniques and formulations to prevent the hatching of nematode eggs in a variety of agricultural, farm-related, and garden-related settings.

Examples of animal parasitic nematodes against which the subject compounds can be used include the following:

- Amblyomma spp.
- Babesia spp. (RBC)
- Bunostomum spp.
- 10 Calliphorid larvae
- Capillaria spp.
- Chabertia ovina
- Chorioptes
- Cooperia spp.
- 15 Cryptosporidium sp.
- Damalinia ovis
- Damalinia caprae
- Demodex
- Dermacentor spp.
- 20 Dicrocoelium dentriticum
- Dictyocaulus filaria
- Echinococcus hydatid cyst
- Eimeria spp.
- Elaeophora schneideri
- 25 Fasciola hepatica
- Fasciola gigantica
- Fascioloides magna
- Giardia sp.
- Gongylonema spp.
- 30 Haematobia irritans
- Haemonchus contortus contortus
- Ixodes
- Linguatula serrata larvae
- Linguatula serrata nymphs
- 35 Linognathus spp.
- M. domestica
- Marshallagia marshalli
- Melophagus ovinus
- Moniezia benedeni
- 40 Moniezia expansa
- Muellerius capillaris
- Musca autumnalis
- Nematodirus spp.
- Oesophagostomum spp.
- 45 Oestrus ovis

- Ornithodoros
- Ostertagia circumcincta
- Ostertagia trifurcata
- Otobius
- 5 Paramphistomum sp.
- Parelaphostrongylus tenuis
- Protostrongylus sp.
- Psoroptes
- Rhipicephalus spp.
- 10 Sarcoptes scabiei
- Sarcocystis spp.
- Sarcocystis spp. cysts
- Schistosoma spp.
- Stomoxys calcitrans
- 15 Strongyloides papillosus
- Taenia hydatigena cysticerci
- Taenia multiceps coenurus
- Taenia ovis cysticerci
- Thelazia
- 20 Thysanosoma actinoides
- Theileria spp.C)
- Toxocara vitulorum
- Toxoplasma gondii
- Toxoplasma gondii cysts
- 25 Trichostrongylus axei
- Trichostrongylus spp.
- Trichuris ovis
- Trypanosoma spp. (plasma)

30 It has been found that helminth, acarid and arthropod endo- and ectoparasitic infestations may be controlled, prevented or eliminated, by applying to, injecting or orally dosing said animals with an endo- or ectoparasitically effective amount of the subject anthelmintic compounds, preferably the above-described Structure 1-46 compounds. This may be achieved by applying the compound to the skin, hide and/or

35 hair of the animals, or injecting or orally dosing said animals with a solid or liquid formulated composition.

For control of flea infestations, treatment of the infested animal to control adults in conjunction with treatment of the area occupied by the infested animal to control flea larvae is recommended. The compositions of the present invention may be admixed with

40 suitable carriers for application to interior and/or exterior areas for control of flea larvae.

The compositions of the present invention may be employed as animal feeds, animal feed premixes or feed concentrates. Feed concentrates and feed premixes, useful in the practice of the invention, may be prepared by admixing about 0.25% to 35% by weight of a subject anthelmintic compound, preferably a Structure 1-46 compound, with
5 about 99.75% to 65% by weight of a suitable agronomic carrier or diluent. Carriers suitable for use include 0.75% to 35% by weight of a physiologically acceptable alcohol such as benzyl alcohol, phenethyl alcohol or propylene glycol, 0 to about 10% by weight of a vegetable oil such as corn oil or soybean oil, or propylene glycol and about 30% to 95% by weight of a sorptive, edible organic carrier such as corn grits, wheat middlings,
10 soybean meal, expanded corn grits, extracted corn meal or the like or a sorptive silica or a silicate. These feed premixes or concentrates may be admixed with the appropriate amount of animal feed to provide the animals with about 0.5 ppm to 1,000 ppm and preferably about 1 ppm to 500 ppm of the compound in the animal's diet. These premixes or concentrates may also be used as top dressings for the animal's daily ration and applied
15 across the top of the daily ration in sufficient amount to provide the animal with about 0.5 ppm to 1,000 ppm and preferably about 1 ppm to 500 ppm of the active ingredient, based on the animal's total feed.

The subject anthelmintic compounds, and particularly the Structure 1-46 compounds, most particularly Structure 22, 23, and Structure 48-290 compounds, may
20 be administered to the animals in or with their drinking water.

The compound may also be administered in the form of a pill, tablet, bolus, implant, capsule, or drench, containing sufficient anthelmintic compound to provide the treated animal with about 0.01 mg/kg to 100 mg/kg of animal body weight per day of the compound. These dosage forms are prepared by intimately and uniformly mixing the
25 active ingredient with suitable finely divided diluents, fillers, disintegrating agents and/or builders such as starch, lactose, talc, magnesium stearate, vegetable gums, or the like. These unit dosage formulations may be varied with respect to the total weight and content of anthelmintic compound depending upon the kind and size of the animal to be treated, the severity or type of infection encountered and the weight of the host.

30 Alternatively, the anthelmintic compound may be administered to animals parenterally, for example, by intraruminal, intramuscular, or subcutaneous injection in

which the active ingredient is dissolved or dispersed in a liquid carrier. For this type administration the compound may be dispersed in a physiologically acceptable solvent for subcutaneous injection, or it may be dispersed in a fat or wax or mixture thereof containing an oil, buffer, surfactant, stabilizer, preservative and salt. Components useful
5 in these preparations include carbowax, aluminum monostearate gel, diethyl succinate, soya oil, glycerol dioleate, saline, and capric/caprylic triglycerides.

The subject anthelmintic compounds may also be applied topically to the larger animals such as swine, sheep, cattle, and horses and companion animals such as dogs and cats in the form of aqueous dips or sprays. For this type administration, the active
10 compound is generally prepared as a wettable powder, emulsifiable concentrate, aqueous flowable, or the like, which is mixed with water at the site of treatment and applied topically to the hide, skin, or hair of the animal. Such sprays or dips usually contain about 0.5 ppm to 5,000 ppm and preferably about 1 ppm to 3,000 ppm of the compound.

Advantageously, the subject anthelmintic compounds may also be prepared as
15 pour-on formulations and poured on the backs of the animals such as swine, cattle, sheep, horses, poultry, and companion animals to protect them against infestation by nematodes, acarids, and arthropod endo- and ectoparasites. Such pour-on compositions are generally prepared by dissolving, dispersing, or emulsifying the anthelmintic compound in a suitable nontoxic pharmacologically acceptable diluent for pour-on and administration.
20 The diluent must be compatible with the compound and should not be a source of irritation or damage to the animals hide, skin, or hair. Such diluents include vegetable oils, spreading oils, polyhydric alcohols, aliphatic or aromatic hydrocarbons, esters of fatty acids, and lower alkyl ketones.

A typical pour-on formulation includes about 0.5% to 30% by weight of the
25 anthelmintic compound, about 30% to 60% by weight of an aliphatic or aromatic hydrocarbon, mono or polyhydric alcohol, lower alkyl ketone or mixtures thereof, 0 to about 20% by weight of a vegetable or mineral oil and about 0.5% to 30% by weight of a spreading oil. Another typical pour-on contains about 45% by weight of xylene, about 15% by weight of the anthelmintic compound, about 10% by weight of corn oil or
30 mineral oil, about 25% by weight of cyclohexanone and about 5% by weight of other pharmacologically acceptable spreading agents, antifoam agents, surfactants, or the like.

The subject anthelmintic compounds may also be prepared as ear tags for animals, particularly quadrupeds such as cattle and sheep. The tags may be prepared by stirring together about 55% to 60% by weight of a vinyl dispersion resin, having an inherent viscosity of about 1.20 and an average particle size of about 0.75 microns, a curing
5 temperature range of about 120°C to 180°C, with about 28% by weight of butylbenzylphthalate. Stirring is continued, and about 1.5% by weight of ca/Zn stearate stabilizer is added along with about 7.0% of the compound and 2.8% of epoxidized soybean oil. The resulting mixture is deaerated for 15 to 20 minutes at 125 mm/Hg. This mixture can be coated on an ear tag blank by dipping and the resulting tag cured at about
10 145°C to 150°C for about five minutes.

The compounds of Formulae I-V, Structure 47, particularly Structures 1-46, and particularly Structures 22, 23, and 48-290 are nematocidal and can be used to control nematodes in crop plants. Therefore, in a further preferred aspect of the invention, there is provided a method for killing or controlling nematodes which comprises applying to
15 the locus of the pests or to a plant susceptible to attack by the pest an effective amount of a compound having any of Structures 1-46, preferably Structure 47, and particularly Structures 22, 23, and 48-290, as defined herein.

The term "controlling" extends to non-lethal effects which result in the reduction or prevention of damage to the host plant or animal and the limitation of nematode
20 population increase. These effects may be the result of chemical induced disorientation, immobilisation, or hatch prevention or induction. The chemical treatment may also have deleterious effects on nematode development, reproduction, or viability.

The compounds of the invention can be used against both plant-parasitic nematodes and nematodes living freely in the soil. Examples of plant-parasitic nematodes
25 are: ectoparasites, for example *Xiphinema* spp., *Longidorus* spp., and *Trichodorus* spp.; semi-endoparasites, for example, *Tylenchulus* spp.; migratory endoparasites, for example, *Pratylenchus* spp., *Radopholus* spp., and *Scutellonema* spp.; sedentary endoparasites, for example, *Heterodera* spp., *Globodera* spp., and *Meloidogyne* spp.; and stem and leaf endoparasites, for example, *Ditylenchus* spp., *Aphelenchoides* spp., and
30 *Hirshmaniella* spp..

The Formulae I-V compounds, Structure 47 compounds, and preferably the compounds of Structures 1-46, more preferably the compounds of Structures 22, 23, and 48-290, display nematicidal activity against different types of nematodes including the cyst nematode. The subject compounds may also be used to combat and control

5 infestations of insect pests such as Lepidoptera, Diptera, Homoptera, and Coleoptera (including *Diabrotica* i.e. corn rootworms) and also other invertebrate pests, for example, acarine pests. The insect and acarine pests which may be combated and controlled by the use of the invention compounds include those pests associated with agriculture (which term includes the growing of crops for food and fiber products), horticulture and animal

10 husbandry, forestry, the storage of products of vegetable origin, such as fruit, grain and timber, and also those pests associated with the transmission of diseases of man and animals. Examples of insect and acarine pest species which may be controlled by the subject compounds include:

- 15 *Myzus persicae* (aphid)
- Aphis gossypii* (aphid)
- Aphis fabae* (aphid)
- Megoura viciae* (aphid)
- Aedes aegypti* (mosquito)
- Anopheles* spp. (mosquitos)
- 20 *Culex* spp. (mosquitos)
- Dysdercus fasciatus* (capsid)
- Musca domestica* (housefly)
- Pieris brassicae* (white butterfly)
- Plutella maculipennis* (diamond back moth)
- 25 *Phaedon cochleariae* (mustard beetle)
- Aonidiella* spp. (scale insects)
- Trialeurodes* spp. (white flies)
- Bemisia tabaci* (white fly)
- Blattella germanica* (cockroach)
- 30 *Periplaneta americana* (cockroach)
- Blatta orientalis* (cockroach)
- Spodoptera littoralis* (cotton leafworm)
- Heliothis virescens* (tobacco budworm)
- Chortiocetes terminifera* (locust)
- 35 *Diabrotica* spp. (rootworms)
- Agrotis* spp. (cutworms)
- Chilo partellus* (maize stem borer)
- Nilaparvata lugens* (planthopper)
- Nephotettix cincticeps* (leafhopper)
- 40 *Panonychus ulmi* (European red mite)

- Panonychus citri (citrus red mite)
- Tetranychus urticae (two-spotted spider mite)
- Tetranychus cinnabarinus (carmine spider mite)
- Phyllocoptura oleivora (citrus rust mite)
- 5 Polyphagotarsonemus latus (broad mite)
- Brevipalpus spp. (mites)

In order to apply the compound to the locus of the nematode, insect, or acarid pest, or to a plant susceptible to attack by the nematode, insect, or acarid pest, the
10 compound is usually formulated into a composition which includes in addition to at least one of the subject anthelmintic compounds suitable inert diluent or carrier materials, and/or surface active agents. Thus, in two further aspects of the invention there is provided a nematicidal, insecticidal, or acaricidal composition comprising an effective amount of a subject anthelmintic compound and preferably of any of Structures 1-46,
15 preferably compounds of Structure 47, more preferably as exemplified by Structures 22, 23, and 48-290, as defined herein and an inert diluent or carrier material and optionally a surface active agent.

The amount of active ingredient generally applied for the control of nematode pests is from 0.01 to 10 kg per hectare, and preferably from 0.1 to 6 kg per hectare.

20 The compositions can be applied to the soil, plant or seed, to the locus of the pests, or to the habitat of the pests, in the form of dusting powders, wettable powders, granules (slow or fast release), emulsion or suspension concentrates, liquid solutions, emulsions, seed dressings, fogging/smoke formulations or controlled release compositions, such as microencapsulated granules or suspensions.

25 Dusting powders are formulated by mixing the active ingredient with one or more finely divided solid carriers and/or diluents, for example natural clays, kaolin, pyrophyllite, bentonite, alumina, montmorillonite, kieselguhr, chalk, diatomaceous earths, calcium phosphates, calcium and magnesium carbonates, sulphur, lime, flours, talc, and other organic and inorganic solid carriers.

30 Granules are formed either by absorbing the active ingredient in a porous granular material for example pumice, attapulgite clays, fullers earth, kieselguhr, diatomaceous earths, ground corn cobs, and the like, or on to hard core materials such as sands, silicates, mineral carbonates, sulphates, phosphates, or the like. Agents which are

commonly used to aid in impregnation, binding or coating the solid carriers include aliphatic and aromatic petroleum solvents, alcohols, polyvinyl acetates, polyvinyl alcohols, ethers, ketones, esters, dextrans, sugars, and vegetable oils with the active ingredient. Other additives may also be included, such as emulsifying agents, wetting agents, or dispersing agents.

Microencapsulated formulations (microcapsule suspensions CS) or other controlled release formulations may also be used, particularly for slow release over a period of time, and for seed treatment.

Alternatively the compositions may be in the form of liquid preparations to be used as dips, irrigation additives or sprays, which are generally aqueous dispersions or emulsions of the active ingredient in the presence of one or more known wetting agents, dispersing agents or emulsifying agents (surface active agents). The compositions which are to be used in the form of aqueous dispersions or emulsions are generally supplied in the form of an emulsifiable concentrate (EC) or a suspension concentrate (SC) containing a high proportion of the active ingredient or ingredients. An EC is a homogeneous liquid composition, usually containing the active ingredient dissolved in a substantially non-volatile organic solvent. An SC is a fine particle size dispersion of solid active ingredient in water. To apply the concentrates they are diluted in water and are usually applied by means of a spray to the area to be treated. For agricultural or horticultural purposes, an aqueous preparation containing between 0.0001% and 0.1% by weight of the active ingredient (approximately equivalent to from 5-2000 g/ha) is particularly useful.

Suitable liquid solvents for ECs include methyl ketone, methyl isobutyl ketone, cyclohexanone, xylenes, toluene, chlorobenzene, paraffins, kerosene, white oil, alcohols, (for example, butanol), methylnaphthalene, trimethylbenzene, trichloroethylene, N-methyl-2-pyrrolidone, and tetrahydrofurfuryl alcohol (THFA).

Wetting agents, dispersing agents, and emulsifying agents may be of the cationic, anionic, or non-ionic type. Suitable agents of the cationic type include, for example, quaternary ammonium compounds, for example cetyltrimethyl ammonium bromide. Suitable agents of the anionic type include, for example, soaps; salts of aliphatic monoesters of sulphuric acid, for example sodium lauryl sulphate; salts of sulphonated

aromatic compounds, for example sodium dodecylbenzenesulphonate; sodium, calcium or ammonium lignosulphonate; or butylnaphthalene sulphonate; and a mixture of the sodium salts of diisopropyl- and triisopropylnaphthalenesulphonates. Suitable agents of the non-ionic type include, for example, the condensation products of ethylene oxide with
5 fatty alcohols such as oleyl alcohol or cetyl alcohol; or with alkyl phenols such as octyl phenol, nonyl phenol, and octyl cresol. Other non-ionic agents are the partial esters derived from long chain fatty acids and hexitol anhydrides, the condensation products of the said partial esters with ethylene oxide, and the lecithins.

These concentrates are often required to withstand storage for prolonged periods
10 and after such storage, to be capable of dilution with water to form aqueous preparations which remain homogeneous for a sufficient time to enable them to be applied by conventional spray equipment. The concentrates may preferably contain 1-85% by weight of the active ingredient or ingredients. When diluted to form aqueous preparations such preparations may contain varying amounts of the active ingredient depending upon the
15 purpose for which they are to be used.

The subject anthelmintic compounds may also be formulated as powders (dry seed treatment DS or water dispersible powder WS) or liquids (flowable concentrate FS, liquid seed treatment LS), or microcapsule suspensions CS for use in seed treatments. The formulations can be applied to the seed by standard techniques and through
20 conventional seed treaters. In use the compositions are applied to the nematodes, to the locus of the nematodes, to the habitat of the nematodes, or to growing plants liable to infestation by the nematodes, by any of the known means of applying pesticidal compositions, for example, by dusting, spraying, or incorporation of granules.

The compounds of the invention may be the sole active ingredient of the
25 composition or they may be admixed with one or more additional active ingredients such as nematicides, agents which modify the behavior of nematodes (such as hatching factors), insecticides, synergists, herbicides, fungicides or plant growth regulators where appropriate.

Suitable additional active ingredients for inclusion in admixture with the
30 compounds of the invention may be compounds which will broaden the spectrum of activity of the compounds of the invention or increase their persistence in the location of

the pest. They may synergise the activity of the compound of the invention or complement the activity for example by increasing the speed of effect or overcoming repellency. Additionally multi-component mixtures of this type may help to overcome or prevent the development of resistance to individual components.

5 The particular additional active ingredient included will depend upon the intended utility of the mixture and the type of complementary action required. Examples of suitable insecticides include the following:

- a) Pyrethroids such as permethrin, esfenvalerate, deltamethrin, cyhalothrin in particular lambda-cyhalothrin, biphenthrin, fenpropathrin, cyfluthrin, tefluthrin, fish
10 safe pyrethroids for example ethofenprox, natural pyrethrin, tetramethrin, s-bioallethrin, fenfluthrin, prallethrin, and 5-benzyl-3-furylmethyl-(E)-(1R,3S)-2,2-dimethyl-3-(2-oxothiolan-3-ylidenem ethyl) cyclopropane carboxylate;
- b) Organophosphates such as profenofos, sulprofos, methyl parathion,
15 azinphos-methyl, demeton-s-methyl, heptenophos, thiometon, fenamiphos, monocrotophos, profenophos, triazophos, methamidophos, dimethoate, phosphamidon, malathion, chlorpyrifos, phosalone, terbufos, fensulphothion, fonofos, phorate, phoxim, pyrimiphos-methyl, pyrimiphos-ethyl, fenitrothion, or diazinon;
- c) Carbamates (including aryl carbamates) such as pirimicarb, cloethocarb,
20 carbofuran, furathiocarb, ethiofencarb, aldicarb, thiofurox, carbosulphan, bendiocarb, fenobucarb, propoxur, or oxamyl;
- d) Benzoyl ureas such as triflumuron or chlorofluazuron;
- e) Organic tin compounds such as cyhexatin, fenbutatin oxide, or azocyclotin;
- f) Macrolides such as avermectins or milbemycins, for example such as
25 abamectin, avermectin, and milbemycin;
- g) Hormones and pheromones;
- h) Organochlorine compounds such as benzene hexachloride, DDT, endosulphan, chlordane, or dieldrin;
- i) Amidines, such as chlordimeform or amitraz;
- 30 j) Fumigant agents;
- k) nitromethylenes such as imidacloprid.

In addition to the major chemical classes of insecticide listed above, other insecticides having particular targets may be employed in the mixture if appropriate for the intended utility of the mixture. For instance, selective insecticides for particular crops, for example stemborer specific insecticides for use in rice such as cartap or buprofezin, can be employed. Alternatively, insecticides specific for particular insect species/stages, for example, ovo-larvicides such as chlofentezine, flubenzimine, hexythiazox, and tetradifon; motilicides such as dicofol or propargite; acaricides such as bromopropylate or chlorobenzilate; or growth regulators such as hydramethylon, cyromazin, methoprene, chlorfluazuron, and diflubenzuron may also be included in the compositions.

Examples of suitable synergists for use in the compositions include piperonyl butoxide, sesamax, safroxan, and dodecyl imidazole.

Suitable herbicides, fungicides, and plant-growth regulators for inclusion in the compositions will depend upon the intended target and the effect required.

An example of a rice selective herbicides which can be included is propanil, an example of a plant growth regulator for use in cotton is "Pix", and examples of fungicides for use in rice include blasticides such as blasticidin-S. The ratio of the compound of the invention to the other active ingredient in the composition will depend upon a number of factors including type of target, effect required from the mixture, etc. However in general, the additional active ingredient of the composition will be applied at about the rate as it is usually employed, or at a slightly lower rate if synergism occurs.

The anthelmintic compounds according to the invention also show fungicidal activity and may be used to control one or more of a variety of plant pathogens. In a further aspect the invention therefore includes a method of combating fungi which comprises applying to a plant, to a seed of a plant, or to the locus of the plant or seed a fungicidally effective amount of a compound as herein defined or a composition containing the same. The invention further includes a fungicidal composition comprising a fungicidally effective amount of a compound as herein defined and a fungicidally acceptable carrier or diluent therefor.

Examples of plant pathogens which the compounds or fungicidal compositions of the invention may control, methods by which fungi may be combatted and the form of suitable compositions, including acceptable carriers and diluents; adjuvants such as

wetting, dispersing, emulsifying, and suspending agents; and other ingredients, such as fertilizers and other biologically active materials, are described, for instance, in International application No. WO 93/08180, the content of which is incorporated herein by reference.

5 All of the U.S. patents cited herein are hereby incorporated by reference.

Following are examples which illustrate procedures for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted. For clarity the following abbreviations shall be used throughout the examples:

10

AC: Acylator

ACD: Available Chemicals Directory

ACN: Acetonitrile

AcOH: Acetic Acid

15

AM: Amine

AUC: Area under curve

BOC: t-Butoxycarbonyl

Hyp-OH: Hydroxyproline

DCM: Dichloromethane

20

DIEA: N,N-Diisopropylethylamine

DIC: 1,3 -Diisopropylcarbodiimide

DMAP: Dimethylaminopyridine

DMF: N,N-Dimethylformamide

DMSO: Dimethylsulfoxide

25

ESI: Electrospray ionization

ESMS: ElectroSprayMassSpectrometry

Fmoc: 9-Fluorenylmethoxycarbonyl

HOBT: 1-Hydroxybenzotriazole

KOH: Potassium hydroxide

30

LC/MS: Liquid Chromatography/Mass Spectroscopy

MS: Mass Spectroscopy

	NMM:	N-Methylmorpholine
	NMP:	N-Methylpyrrolidinone
	Pyr:	Pyridine
	S:	Scaffold
5	SLE:	Solid liquid-liquid extraction
	THF:	Tetrahydrofuran
	TFA:	Trifluoroacetic acid
	TLC:	Thin layer chromatography
	dH ₂ O	Distilled Water

10

Example 1 – Preparation of Anthelmintic Compounds 1-46

The anthelmintic compounds of the subject invention can readily be produced using procedures well known to those skilled in the art.

15 A variety of anthelmintic compounds useful according to the subject invention can be readily prepared by a person skilled in this art having the benefit of the subject disclosure.

Example 2 – Nematicidal Activity of Anthelmintic Compositions 1-31

20 *Caenorhabditis elegans* adults were grown on Nematode Growth Medium (NGM) until they produced eggs, then the adults were removed.

The eggs were allowed to hatch, and the L1 larvae collected. See *The Nematode Caenorhabditis elegans* (1988) Cold Spring Harbor Laboratory Press. Using a Matrix Programmable Pipette, the L1s were distributed into 96-well tissue culture plates, 20 L1 in 50 μ l NGM per well. Antibiotic/Antimycotic was added to each well, and 1% by weight
25 *E. coli* strain HB101. The subject anthelmintic compounds were stored at 5mM in 100% DMSO. 0.7 μ l of compounds 1-31 were added to the left-most column of wells to yield a final concentration of 70 μ M in 1.4% DMSO, with 1.4% DMSO only as the control. The compounds were then subjected to 5 more 3-fold dilutions from left to right to yield 6 column concentrations of 70 μ M, 23.3 μ M, 7.8 μ M, 2.6 μ M, 0.9 μ M, and 0.3 μ M. Plates
30 were stored in air-tight Rubbermaid plastic boxes at 20°C. The nematodes had cleared all control wells by day 4, and nematode viability was scored by visual examination

under a 100x dissecting microscope on day 5. A visual viability scoring system was used as follows:

WORM VISUAL SCORING GUIDE

5	<u>Lethality:</u>		
	Dead	only stiff L1s (no movement)	
	Dead (L4)	worms are dead, but at a later larval stage	
	L1	majority of worms are L1 (based on size)	
10		worms move when plate is tapped	
	L2	majority of worms are L2 (based on size)	
	L3	majority of worms are L3 (based on size)	
	L4	majority of worms are L4 (based on size)	
15	<u>Partial Penetrance:</u>		
	AD	majority of worms are adult	
	#AD	5 adult worms or less	
	<u>Broodsize Reductions:</u>		
20	B!	sterile	(0 – 25 progeny)
	B	low broodsize	(25 – 100 progeny)
	~B	moderate broodsize	(100 – 250 progeny)
	<	reduced broodsize	(250 – 500 progeny)
	OK	no effect	(~ 1000+ progeny)

25

If several classes of worms exist in a well, then all classes are scored. If adults are present, then the brood score is also recorded. Thus, "L1/L2" would mean a mixture of L1's and L2's are present in the well. "L4/#AD/B" would mean that a mixture of L4's and adults are present in the well. The "#AD" would mean that there are 6 or less adults, and the "B" would mean that there were 100 progeny or less.

30

The results are reported in Table 1. Column V1 has a compound concentration of 70 μ M with sequential 3-fold dilutions reported in columns V2, V3, V4, V5, and V6, respectively, such that the V6 concentration was 0.3 μ M.

Table I.

Dose Response Tracking				5 Day Visual Score						
DR#	ITS Tracking Library #	Structure#	Source P	Well Address	V1	V2	V3	V4	V5	V6
1375	AKC 111	1	N2 #93	5081:D10	Dead	Dead	1.2	Dead(1.3/L	//AD/B	OK
1647	AKC 112	2	N2 #98	5090:A10	1.2/L3	1.2/L3	1.2/L3	1.3/L4	//AD/-B	OK
1466	AKC 113	3	N2 #85	5061:A10	Dead	Dead	Dead	Dead(L2/L	L2/Dead(A	L4//AD//B
1469	AKC 107	4	N2 #86	5061:D10	Dead	Dead(1.2/L3)	1.2/L3	Dead(L4)	1.4/Dead(A	1.2/Dead(
1477	AKC 114	5	N2 #86	5061:D11	Dead	1.3/Dead(L4)	1.3	1.3/Dead(L	1.2/L3	-B
1476	AKC 108	6	N2 #86	5061:C11	Dead	Dead	1.1	1.1	1.1/L2	1.2/L3
1473	AKC 115	7	N2 #86	5061:H10	Dead	Dead(1.2/L3)	1.2/Dead(L2)	Dead(1.2)	Dead(1.2/L	1.2/L3
035	AKC 119	11	N2 #126	5393:B1	//AD/B	//AD/B	//AD/B	//AD/B	//AD/B	<
2059	AKC 110	12	N2 #128	5399:C4	1.1	1.1	1.1	1.1	1.1	1.1
2083	AKC 120	13	N2 #130	5419:C4	1.1	1.2/L3	1.1	1.1/L2	//AD/-B	OK
2032	AKC 121	14	N2 #126	5389:C4	1.1	1.1	1.1/L2	//AD/-B	//AD/B	<
2029	AKC 2153	15	N2 #126	5379:C4	1.1	1.1	1.1/L2	//AD/B	//AD/B	//AD/B
1962	AKC 122	16	N2 #121	5373:B8	Dead	1.1	//AD/B	//AD/B	//AD/B	OK
1388	AKC 104	17	N2 #80	5022:C4	1.1/L2	1.1/L2	1.1/L2	//AD/B	1.1/L2	1.1/L2
1372	AKC 123	18	N2 #79	5016:B8	1.1	1.1/L2	//AD/B	<	//AD/B	//AD/-B
1402	AKC 124	19	N2 #81	5033:D8	//AD/B	//AD/B	1.2/L3	1.4//AD/B	1.4//AD/B	1.4//AD/B
1396	AKC 125	20	N2 #80	5031:G8	1.2/Dead(1.3)	1.2/Dead(1.3)	1.2	1.2	//AD/B	<
1393	AKC 105	21	N2 #80	5031:G2	1.2/Dead(1.3)	1.2/Dead(1.3)	1.2/Dead(1.3)	1.2/Dead(1	1.2/Dead(L	1.2/Dead(L
1164	AKC 126	22	N2 #64	4724:E10	1.1/L2	1.1/L2	1.1/L2	//AD/-B	-B	//AD/B
1174	AKC 102	23	N2 #65	4727:E8	1.1/L2	1.1/L2	1.2/L3	1.3	//AD/B	B
806	AKC 103	24	N2 #149	4470:D10	1.1/L2	Dead(1.3/L4)	Dead(1.4)	B	1.4//AD/B	<
18	AKC 171	25	N2 #2	2606:A1	Dead	1.2	Dead(1.4//A	1.2/L3	<	1.2/L3
433	AKC 128	26	N2 #31	3313:A10	Dead	Dead	Dead	1.1	//AD/-B	OK
506	AKC 129	27	N2 #37	3315:A10	Dead	Dead	1.1/L2	1.1/L2	OK	1.1/L2
484	AKC 130	28	N2 #35	3314:D10	Dead	//AD/-B	//AD/B	//AD/-B	OK	//AD/B
486	AKC 131	29	N2 #35	3314:F10	Dead	1.1	//AD/-B	//AD/-B	//AD/-B	<
568	AKC 132	30	N2 #41	3323:C4	Dead(1.2)	Dead	Dead	//AD/B	//AD/B	Dead
569	AKC 133	31	N2 #41	3323:H1	Dead	Dead	Dead	Dead	Dead	Dead
187	AKC 340	32	N2 #14	2665:B5	1.1	1.1	//AD/B	//AD/B	//AD/B	B
133	AKC 134	33	N2 #10	2640:A11	Dead	Dead	Dead	//AD/B	//AD/B	OK
149	AKC 135	34	N2 #11	2641:A8	Dead	1.1	1.1/L2	//AD/B	-B	//AD/B
CONTROL					OK	OK	OK	OK	OK	OK

Example 3 – Nematicidal Activity of Anthelmintic Compositions 32-46

The *C. elegans* nematode activity assay for anthelmintic compounds 32-46 was similar to that described in Example 2 above, except for the following noted differences. The compound concentrations were adjusted to 140 μ M and subjected to 2-fold dilutions to yield 140 μ M, 70 μ M, 35 μ M, 17.5 μ M, 8.8 μ M, 4.4 μ M, 2.2 μ M, and 1.09 μ M. The visual evaluation of viability was conducted at Day 4, and the results are presented in Table 2.

10

Table 2.

Compound	μ M Concentration							
	140	70	35	17.5	8.8	4.4	2.2	1.09
AKC-138	L1	L1	L1	L2	~B	OK	OK	OK
AKC-144	L3/L4	L4/AD/B	B	~B	OK	OK	OK	OK
AKC-141	L1	L1	L1	<	OK	OK	OK	OK
AKC-116	L1/L2	L2/L3	L3	B!	B	OK	OK	OK
AKC-117	L1/L2	L2/L3	L3	B!	B	<	OK	OK
AKC-118	L2	L2/L3	L3	L4/AD/B!	B	~B	OK	OK
Control	OK	OK	OK	OK	OK	OK	OK	OK

20

Example 4 - Activity Against Nematode (*C. elegans*) Eggs

Compositions of the subject invention are surprisingly found to be ovicidal. The following procedures are used to test for lethal effects against nematode eggs.

25

Materials

As referred to herein, "S Medium" refers to "S basal" supplemented with CaCl₂, MgSO₄, and a trace metals solution as follow:

30

S basal

47

	NaCl	5.857 g
	1M potassium phosphate (pH 6)	50.0 ml
	Cholesterol (5mg/ml in EtOH)	1.0 ml
	dH ₂ O	_____
5		1 L

The above preparation is then autoclaved. S basal can be stored until needed.

Just prior to use, S Medium is made from S basal by adding, aseptically, the following components to 1L S basal (components should first be autoclaved separately):

	1M potassium citrate (pH 6)	10 ml
10	Trace metals solution (see below)	10 ml
	1M CaCl ₂	3 ml
	1M MgSO ₄	3 ml
	<u>Trace Metals solution</u>	
15	Na ₂ EDTA	1.86 g (to 5mM)
	Fe ₂ SO ₄ • 7H ₂ O	0.69 g (to 2.5mM)
	MnCl ₂ • 4H ₂ O	0.20 g (to 1mM)
	ZnSO ₄ • 7H ₂ O	0.29 g (to 1mM)
	CuSO ₄ • 5H ₂ O	0.025 g (to 0.1mM)
20	dH ₂ O	_____
		1 L

Procedure:

1. Make anthelmintic compound dilutions as indicated in Examples 2-3.
- 25 2. To 500 µl of each dilution, added 10 µl of eggs (estimated >200 eggs/10 µl).
3. Mixed well and allowed to incubate at room temperature for from 30 minutes to 3 hours.
4. Centrifuge at 2000 rpm for 5 minutes at room temperature.
- 30 5. Pipette off supernatant.
6. Re-suspend in 500 µl S Medium.

7. Centrifuge at 2000 rpm for 5 minutes at room temperature
8. Pipette off supernatant.
9. Re-suspend in 300 µl S Medium.
10. Transfer 300 µl into 24-well tissue culture bioassay tray.
- 5 11. Add 2 µl of stationary phase *E. coli* to each well.
12. Score after 3 days at room temperature in the dark.

Example 5 – Additional Observations of Activity Against Nematode (*C. elegans*) Eggs

Additional tests are conducted to confirm the ovicidal activity. The following
10 procedures are used.

1. Make anthelmintic compound dilutions to 2X concentrations shown in Example 4.
2. Distribute 0.5 ml of each dilution into 1.5-ml Eppendorf tubes.
3. Add 0.5 ml of *C. elegans* egg preparation to 0.5 ml 2X dilution to yield
15 final exposure concentration.
4. Mix well and allow to incubate at room temperature for from 30 minutes to 3 hours.
5. Centrifuge at 2000 rpm for 5 minutes at room temperature.
6. Pipette off supernatant and re-suspend in 1.5 ml S Medium.
- 20 7. Spin as above for 2 minutes.
8. Pipette off supernatant and re-suspend in 1.5 ml S Medium.
9. Repeat #7.
10. Pipette off supernatant and re-suspend in 1.0 ml S Medium.
11. Add 280 µl of S Medium to each well of 24-well tissue culture plate.
- 25 12. Add 20 µl of each treated (and control) sample in triplicate into the respective wells.
13. Score after 3 days at room temperature in the dark.

Example 6 – Preparation of Anthelmintic Compounds 47, as specifically exemplified by
30 Compounds 48 -290

While the anthelmintic compounds of the subject invention can readily be produced using procedures well known to those skilled in the art, the following is a preferred method of producing anthelmintic Compounds 47, and exemplified Compounds 48-290, as shown in Figures 48-290. The general library scheme resulting in Compounds 47 is depicted in Figure 291. Scaffolds 1-6, depicted in Figures 292-297, are convenient intermediates for generating Compounds 47, and can be made from boc-hydroxyproline.

Scaffold Synthesis.

In a 2 L Morton three-neck flask equipped with mechanical stirrer, finely powdered 85% KOH (93.50 g, 1.666 mol, EM Biosciences) was dissolved in DMSO (400 mL, Aldrich, HPLC grade) under an atmosphere of nitrogen. After stirring at ambient temperature for 15 min, the apparatus was stirred and cooled with an ice-water bath for 10 min. After this 10 min period, Boc-Hyp-OH (48.59 g, 0.210 mol, Novabiochem) was added in one portion. DMSO (ca. 10 mL) was used to rinse residual Boc-Hyp-OH off the neck of the flask. After stirring for 5 min, the completely homogeneous solution was treated with one portion of 3-methoxybenzyl bromide (187 g, 0.928 mol) to initiate synthesis of Scaffold 6 (Figure 297). DMSO (10 mL) was used to rinse residual 3-methoxybenzyl bromide off the neck of the flask. Other precursors useful in scaffold synthesis are listed in Table 8, where the "Entry" column corresponds to the Scaffold number desired. Caution: Alkylating agents are lacrymators and highly corrosive. Solutions of DMSO can potentially be highly toxic. After stirring at 0 °C for 15 min, the reaction mixture was warmed up to ambient temperature for 4 h. The reaction was monitored by the following procedure: the reaction mixture (0.5 mL) was aliquoted to a 4 mL glass vial and diluted with water (1 mL). The aliquot was acidified with 1 M aqueous KHSO₄ (0.5 mL) to pH 2-3 (tested by pH paper). Diethyl ether (2 mL) was added to the acidic mixture. The sample in the organic phase was analyzed by TLC (9:1 CH₂Cl₂/MeOH) by UV light and Ninhydrin spray. After the reaction was judged complete after 4 h by TLC, the reaction mixture was poured into water (1.2 L) in a 2 L Erlenmeyer flask. The Morton flask was rinsed with an additional portion of water (400 mL), and the aqueous wash was transferred into the Erlenmeyer flask. After stirring at ambient temperature for 5 min, the suspension was washed with diethyl ether (2x 1.2 L).

The aqueous phase was acidified with 87% concentrated H_3PO_4 (150 mL) to pH 2-3 (tested by pH paper). This solution was then extracted diethyl ether (2x 1.2L). The combined ether layers were washed with water (2x 650 mL), and saturated aqueous NaCl (2x 700 mL). The organic layer was dried over anhydrous MgSO_4 (VWR) for 30 min, 5 filtered, and concentrated in vacuo. The crude material was then triturated with hexane twice and concentrated in vacuo overnight.

The following procedure was used for scaffold 1, 2, and 6, Figures 292, 293, and 297, but was not used for scaffold 3, 4, and 5, Figure 294, 295, and 296. A solution of crude product in diethyl ether (1L) was treated with cyclohexylamine (18 mL, 0.210 10 mol). Upon precipitation, the mixture was cooled with an ice bath, stirred for 20 min, and filtered through a Buchner funnel under vacuum. The complex was washed with diethyl ether (2x 250 mL) and hexane (2x 250 mL), and air-dried overnight.

A solution of the complex in water (500 mL) and diethyl ether (350 mL) was stirred at ambient temperature until all solid material dissolved. The solution was then 15 acidified with 87% concentrated H_3PO_4 (40 mL) to pH 2-3. In a 1 L separatory funnel, the organic layer was separated from the aqueous layer. The aqueous layer was extracted with diethyl ether (350 mL). The combined organic layers were washed with 0.5 M KHSO_4 (350 mL), water (250 mL) and saturated aqueous NaCl (2x 300 mL). The combined organic layers were dried over anhydrous MgSO_4 for 15 min, and filtered. 20 Concentration in vacuo provided 72.0 g (98%) of scaffold 6 as a yellow oil.

Step A. Carboxylic Acid Coupling.

DIC (0.824 mL, 5.265 mmol) was added to a CH_2Cl_2 solution (6 mL) of carboxylic acid from Step A (5.265 mmol) and the solution was allowed to sit for 15 min 25 with occasional swirling. The mixture was then added to the thiophenol resin (1.5 g, 1.755 mmol). The vial was rinsed with CH_2Cl_2 (5 mL), and this solution was added to the resin. DMAP (0.214 g, 1.755 mmol) was then added to the slurry, and the mixture was shaken for at least 18 hr. The resin was then washed using the following solvents; (CH_2Cl_2 , THF) 4x; CH_2Cl_2 4x, MeOH 3x. The resin was then dried on high vacuum 30 overnight (ca. 16 h). The resin loading was determined by mass analysis as a percentage of theoretical. The resin was also qualitatively analyzed by IR, and an FeCl_3/pyr test.

Step B. Resin Plating.

The resin from Step A (ca. 100 mg per well using flat well Falcon Plates) was placed in the wells of a clamped polyfilitronics microtiter plate (2.7 μ M, GF/D) following the T.O.P #APD-602 "Resin transfer with Falcon (Rev. Code: 20 Apr 1998 DGP)."

5

Step C. Deprotection.

Both Steps C and D must be done sequentially on the same day. Using a Moduline, the resins were washed with CH_2Cl_2 2x. After placing plates in Hydra clamps, a solution (1 mL/well) of TFA/ CH_2Cl_2 /anisole (50:48:2) was added by a Robbins Hydra.

10 The plate was covered with a teflon sheet and clamped. Wells should point upward. The plates are shaken on a reciprocal shaker for 1 h. After freezing the bottom of the plates in dry ice, the plates are unclamped and TFA allowed to drain. Using a Moduline, the resin was then washed using the following solvents, CH_2Cl_2 3x, 20% $\text{Et}_3\text{N}/\text{CH}_2\text{Cl}_2$ 3x, MeOH 3x, CH_2Cl_2 3x. The plates are placed back into a Hydra clamp with a Teflon sheet
15 on the bottom.

Step D. Acylation.

Both Steps C and D must be done sequentially on the same day. Four different classes of reagents are used to acylate the unreactive 4-aminoalkyl substituent: sulfonyl
20 chlorides (see Table 9), acid chlorides (see Table 9), isocyanates and isothiocyanates. Each acylator is dissolved in 0.702 M DIEA in CH_2Cl_2 and diluted to 0.351 M with CH_2Cl_2 . A solution of each acylator (1 mL/well) was added to the appropriate well. The plate was clamped, and shaken overnight (ca. 16 h) on a reciprocal shaker. Wells should point upward. Using a Moduline, the resins were washed using the following solvents,
25 (CH_2Cl_2 , then MeOH) repeat 4x, CH_2Cl_2 4x. The plate is placed back into a Hydra clamp with a Teflon sheet on the bottom.

Table 8

Alkyl bromides and iodides.

These precursors were used in the scaffold synthesis.
















Entry	ACD	MW	Amount	Name	Structure
1	172	171.04	342 g	Benzyl bromide	
2	257	199.1	255 g	1-Bromo-3-phenylpropane	
3	1098	184.02	259 g	1-Iodobutane	
4	1509	177.09	345 g	(Bromomethyl) cyclohexane	
5	180	227.15	396 g	4-tert-Butylbenzyl bromide	
6	216590	201.07	301 g	3-Methoxy benzylbromide	









Table 9

Acid chlorides and sulfonyl chlorides.

The amount listed here is for one scaffold, which is a set of 12 plates, in the production library.

The final concentration is 0.351 M and the total volume is 50 mL.

Entry	ACD	MW	Amount(g)	Name	Structure
1	653	140.568 d=1.211	2.467	Benzoyl chloride	
2	665	200.62	3.521	2,6-Dimethoxybenzoyl chloride	
3	668	154.595 d=1.185	2.713	o-Toluoyl chloride	
4	675	230.646	4.048	3,4,5-Trimethoxybenzoyl chloride	
5	689	212.675 d=1.122	3.732	4-n-butoxybenzoyl chloride	
6	696	154.595 d=1.169	2.713	p-Toluoyl chloride	
7	719	78.4977 d=1.104	1.378	Acetyl chloride	
8	728	108.524 d=1.197	1.905	Methoxyacetyl chloride	
9	745	92.53 d=1.065	1.624	Propionyl chloride	
10	1456	146.616 d=1.096	2.573	Cyclohexanecarbonyl chloride	

Entry	ACD	MW	Amount(g)	Name	Structure
					
11	3985	269.751	4.734	Dansyl chloride	
12	7450	190.649	3.346	p-Toluenesulfonyl chloride	
13	9674	214.647	3.767	3,4-Dimethoxyphenylacetyl chloride	
14	9929	176.549 d=1.425	3.098	2,5-Difluorobenzoyl chloride	
15	12046	214.647	3.767	2,5-Dimethoxyphenylacetyl chloride	
16	13655	230.693	4.049	Diphenylacetyl chloride	
17	17527	200.62	3.521	2,4-Dimethoxybenzoyl chloride	































Entry	ACD	MW	Amount(g)	Name	Structure
18	24872	236.674	4.154	2,5-Dimethoxybenzenesulfonyl chloride	
19	41509	246.757	4.331	4-tert-Amylbenzenesulfonyl chloride	
20	44947	232.749 d=1.04	4.085	(-)-Menthoxycetyl chloride	
21	46426	234.681	4.119	2-Ethoxy-1-naphthoyl chloride	
22	51569	198.648	3.486	2-Phenoxybutyryl chloride	
23	51769	236.674	4.154	3,4-Dimethoxybenzenesulfonyl chloride	
24	74724	198.691	3.487	1-Adamantanecarbonyl chloride	

Table 10

Amine Diversity Elements.

Entry	ACD	MW	Amount (g)	Name	Structure
1	3799	133.19 d=1.038	1.172	1-Aminoindane	
2	4014	171.242 d=1.063	1.507	(+/-)-1-(1-Naphthyl)ethylamine	
3	4731	117.191 d=1.2	1.031	L-Isoleucinol	
4	4732	151.208	1.331	L-Phenylalaninol	
5	4734	117.191 d=0.917	1.031	D-Leucinol	
6	8079	151.208	1.331	(1R,2S)-(-)-Norephedrine	
7	8085	75.1101 d=0.943	0.661	DL-2-Amino-1-propanol	
8	8090	149.236 d=0.922	1.313	1-Methyl-3-phenylpropylamine	
9	8107	125.15 d=1.095	1.101	2-Fluorobenzylamine	
10	8110	137.18 d=1.051	1.207	2-Methoxybenzylamine	

Entry	ACD	MW	Amount (g)	Name	Structure
11	8137	137.181	1.207	2-Amino-1-phenylethanol	
12	8139	75.1101 d=0.973	0.661	1-Amino-2-propanol	
13	8183	61.0833 d=1.012	0.538	Ethanolamine	
14	8188	181.234 d=1.074	1.595	3,4-Dimethoxyphenethyl amine	
15	11690	73.1379 d=0.740	0.644	n-Butylamine	
16	14820	70.0944 d=0.914	0.617	3-Aminopropionitrile	
17	17150	197.232 d=1.155	1.736	3,4,5-Trimethoxybenzyl amine	
18	21279	181.321 d=0.93	1.596	o-Aminobicyclohexyl	
19	25572	186.051 d=1.480	1.637	2-Bromobenzylamine	
20	25622	131.22 d=0.853	1.155	3-Butoxypropylamine	
21	40754	163.262 d=0.881	1.437	4-tert-Butylbenzylamine	
22	41323	139.172 d=1.059	1.225	4-Fluoro-α-methylbenzylamine	
23	41898	105.204 d=0.953	0.926	3-(Methylthio)propylamine	

Entry	ACD.	MW	Amount (g)	Name	Structure
24	52392	167.207 d=1.130	1.471	2,3-Dimethoxybenzyl amine	
25	52393	167.207 d=1.113	1.471	2,4-Dimethoxybenzyl amine	
26	52975	137.181 d=1.048	1.207	2-Phenoxyethylamine	
27	59019	128.174	1.128	3-Acetamidopyrrolidine	
28	59040	186.253	1.639	3-(tert-butoxycarbonyl amino) pyrrolidine	
29	60612	190.072 d=1.28	1.673	2,6-Dichlorophenethyl amine	
30	60613	181.234 d=1.09	1.595	2,3-Dimethoxy phenethyl amine	
31	60614	181.234 d=1.09	595	2,5-Dimethoxy phenethyl amine	
32	60618	181.234 d=1.07	1.454	3,5-Dimethoxy phenethyl amine	
33	60620	165.234 d=0.99	1.682	4-Ethoxyphenethylamine	
34	61237	191.151 d=1.252	1.682	4-(Trifluoromethoxy) benzylamine	

Entry	ACD	MW	Amount (g)	Name	Structure
35	61267	191.151 $\alpha=1.252$	1.349	3-(Trifluoromethoxy) benzylamine	
36	66934	153.267 $d=0.902$	1.075	1,3,3-Trimethyl-6-azabicyclo(3.2.1)octane	
37	75408	122.17	1.225	2-Aminobenzylamine	
38	75502	139.172 $d=1.066$		2-Fluorophenethylamine	
39	75513	122.17 $d=1.078$	1.075	4-Aminobenzylamine	
40	79755	195.26 $d=1.05$	1.718	3-Ethoxy-4-methoxy phenethylamine	
41	134208	139.172 $d=1.076$	1.225	4-Fluorophenethylamine	
42	191368	115.175	1.014	2-Aminocyclohexanol	
43	191602	164.25 $d=1.00$	1.445	<i>n</i> -(3-Aminopropyl)- <i>n</i> -methylaniline	
44	192238	153.267 $d=0.909$	1.349	(1R,2R,3R,5S)-(-)-Isopinocampheylamine	

Step E. Product Cleavage.

After washing with dioxane 2x, the resin from Step D was treated with the appropriate amine (0.8 mL of a 0.4 M solution in 1,4-dioxane, 0.32 mmol), selected from those listed in Table 10. The plates were shaken on a reciprocal shaker in a clamped
5 plate at ambient temperature for 48 h. Wells should point upward. After the bottoms of the plates are frozen, polyfiltronics plate is placed on a Beckman square well plate and the crude products collected. The resins were washed with 1,4-dioxane (0.35 mL, 2x). After freezing the dioxane solutions in -80 °C freezer for 1 h, the products are lyophilized for at least 4 h.

10 Step F. SLE.

Removal of the excess amine starting material was accomplished by solid phase liquid-liquid extraction using Varian Chem Elut material packed into a polyfiltronics plate (10 micron PP/P). The Chem Elut (≈ 2.0 g) is treated with 2.0 N HCl (0.6 mL per well) followed by addition of the above product from Step E in 4:1 $\text{CH}_2\text{Cl}_2/\text{THF}$ (1 mL).
15 After allowing the product solution to elute for 15 min into the Beckman plate, the source plate was washed with 4:1 $\text{CH}_2\text{Cl}_2/\text{THF}$ (0.350 mL), and each wash was transferred immediately to the SLE plate. Each 4:1 $\text{CH}_2\text{Cl}_2/\text{THF}$ wash was allowed to drain for 15 min. The products were then concentrated in vacuo with Genevac following S.O.P. #APC-203-000 "Genevac Evaporator (Rev. Code: 23 July 1998 BW)" and analyzed by
20 LC and MS.

Development.

Early Development: Several synthetic pathways were explored for the library synthesis of hydroxyproline derivatives. After amine addition to bromomethyl Wang
25 resin, Fmoc-Hyp-OH was coupled to solid-supported amine with DIC (5 eq.) and HOBt (2.5 eq.) in NMP. PyBrop (2 eq.), and DIEA (4 eq.) in DCM also gave the desired product, as shown in Figure 298. However, the Mitsunobu reaction in polyfiltronics plates failed. Heat generated from the high reaction concentration and poor mixing contributed to the failure of this reaction. In some cases, intramolecular cyclization or
30 elimination occurred during the Mitsunobu reaction. Cleavage of linker was also observed.

As shown in Figure 299, an alternate route required coupling Fmoc-Hyp-OH on bromomethyl Wang resin, and introducing the final diversity element in solution as the last step.

Figure 300 depicts the result of using diamines on nitrophenol carbonate linker,
5 which gave low yield of the desired product.

Solution phase syntheses of scaffolds functionalized with the first diversity element were then considered as a strategy for library generation. After introduction of the phenols on the hydroxyproline scaffold via Mitsunobu reaction, extensive chromatographic purification and low yields of these scaffolds made this route less
10 desirable for library generation. Accordingly, the original protocol was modified to allow for alkylation on the alcohol moiety of the hydroxyproline, and a preferred library synthesis was the result. (Figure 301).

Scaffold Synthesis.

15 A practical synthesis of alkylated hydroxyproline scaffolds was developed. The alkylation was driven to completion using 400 mol% instead of 200 mol% excess alkylating reagent. The reaction was executed under an atmosphere of nitrogen because KOH is hygroscopic. DMSO also needs to be anhydrous. In the work up procedure, H_3PO_4 is the preferred acidifying agent since the use of $KHSO_4$ resulted in the
20 precipitation of solids. Cyclohexylamine was also used to remove an unknown byproduct. No chromatography was involved in the syntheses.

Scaffold Coupling.

After scaffolds were coupled using DIC/DMAP, coupling was confirmed by
25 $FeCl_3$ /pyridine test. The test was performed by dissolving about 50 mg of resin in pyridine (0.5 mL) and adding a 0.5 M chloroform solution of $FeCl_3$ (0.5 mL). The resin was washed with CH_2Cl_2 and examined. Any color change to a dark color indicates free thiophenol. With free thiophenol resin, the beads will turn dark green-black. The test will indicate no free phenol if no color change from original resin color is observed. This
30 is not a quantitative test, but a qualitative measure of resin loading.

Acylation.

Acid chlorides, sulfonyl chlorides, isocyanates, and isothiocyanates were generally soluble in DCM. Carboxylic acids were generally soluble in DMF.

5 Amine cleavage.

a. Although pyridine is reported to be a suitable solvent for cleavage, 1,4-dioxane also worked well.

b. Secondary amine cleavage requires much more time (36-48 h) than the primary amine cleavage (24 h).

10

SLE.

a. 4:1 CH_2Cl_2 /THF used as elution solvent for SLE. In CH_2Cl_2 , some products were insoluble.

b. Priming volume increased from 0.4 mL to 0.6 mL of 2 N HCl per well.

15

Plating.

After SLE, 4:1 ACN/MeOH used to dissolve products for QC samples.

Example 7 Nematicidal Activity of Anthelmintic Compositions 48-290

20 The nematicidal activity of anthelmintic Compositions 48-290 were determined in accordance with the procedure outlined in Example 2. The results are reported in Table 3.

HTS Tracking				Initial HTS Run				Follow-up HTS Run				5 Day Visual Score					
AKC #	MP #	Well	mOft % Run	Visual Score	mOft % Run	Visual Score	Well Addr	V1	V2	V3	V4	V5	V6				
1259	4715 A7	169	83% Dead		181	118% 4AD/B	4715:A7	L1	<	OK	OK	OK	OK				
1260	4715 B7	187	92% Dead		203	133% L1/L2	4715:B7	L1	<	OK	OK	OK	OK				
1261	4715 C7	196	96% Dead		197	129% L1/L2	4715:C7	L1	~B	OK	OK	OK	OK				
1262	4715 D7	182	89% Dead		191	125% L1/L2	4715:D7	L1	~B	OK	OK	OK	OK				
1263	4715 E7	200	98% Dead		207	135% 1AD/BI	4715:E7	L1	#AD/~B	OK	OK	OK	OK				
1264	4715 F7	206	101% Dead		195	127% 1AD/BI	4715:F7	L1	L1	L1/L2	OK	OK	OK				
1265	4715 G7	203	100% Dead		188	123% L1/L2	4715:G7	L1	#AD/B	OK	OK	OK	OK				
1266	4715 H7	197	97% Dead		180	118% 2AD/BI	4715:H7	L1	#AD/~B	OK	OK	OK	OK				
1267	4715 E9	208	102% L1/L2/L3		201	131% B - AD Husks	4715:E9	L2/L3	<	OK	OK	OK	OK				
1268	4715 E10	198	97% Dead		198	129% 4AD/B	4715:E10	L1	~B	OK	OK	OK	OK				
1269	4715 F10	193	95% Dead		202	132% 3AD/B	4715:F10	L1	OK	OK	OK	OK	OK				
1270	4715 G10	195	96% Dead/1AD		192	125% 4AD/B	4715:G10	L1	<	OK	OK	OK	OK				
1271	4715 H10	193	95% 1L3/1L4		171	112% B	4715:H10	BI	BI	OK	OK	OK	OK				
1272	4716 A7	166	81% Dead		191	125% Dead	4716:A7	#AD/BI	OK	OK	OK	OK	OK				
1273	4716 B7	189	93% Dead		212	139% L1/L2	4716:B7	L1/L2	<	OK	<	OK	OK				
1274	4716 C7	183	90% Dead		200	131% 3AD/BI	4716:C7	L1	#AD/B	OK	OK	OK	OK				
1275	4716 D7	180	88% Dead		195	127% 1AD/BI	4716:D7	L1	<	OK	OK	OK	OK				
1276	4716 E7	184	90% Dead		198	129% L1/L2	4716:E7	L1	<	OK	OK	OK	OK				
1277	4716 F7	197	97% Dead		207	135% 1AD/BI	4716:F7	L1	<	OK	OK	OK	OK				
1278	4716 G7	201	99% Dead		199	130% L1/L2	4716:G7	L1	L1	L1	OK	OK	OK				
1279	4716 H7	201	99% Dead		170	111% B	4716:H7	L1	#AD/B	OK	OK	OK	OK				
1280	4716 F10	201	99% Dead/1AD		182	119% B	4716:F10	L1	OK	OK	OK	OK	OK				
1281	4717 A7	169	83% Dead		190	124% 3AD/BI	4717:A7	L1/L2	OK	OK	OK	OK	OK				
1282	4717 B7	186	91% Dead		220	144% L1/L2	4717:B7	L1	<	OK	<	OK	OK				
1283	4717 C7	195	96% Dead		204	133% 3AD/BI	4717:C7	L1	~B	OK	OK	OK	OK				
1284	4717 D7	182	89% Dead		201	131% 1AD/BI	4717:D7	L1	~B	OK	OK	OK	OK				
1285	4717 E7	197	97% Dead		218	142% 2AD/BI	4717:E7	BI	#AD/B	OK	OK	OK	OK				
1286	4717 F7	192	94% Dead		218	142% L1/L2	4717:F7	L1	BI	OK	OK	OK	OK				
1287	4717 G7	206	101% Dead		198	129% 2AD/B	4717:G7	L1	~B	OK	OK	OK	OK				
1288	4717 H7	212	104% Dead		184	120% 5AD/B	4717:H7	L1	#AD/B	OK	OK	OK	OK				
1289	4717 D10	192	94% L1/1L4		191	125% 0AD/BI - AD Husks	4717:D10	L1	<	OK	OK	OK	OK				
1290	4717 E10	196	96% Dead		195	127% 2L4/3AD/B	4717:E10	L2/L3	L4/#AD/BI	~B	OK	OK	OK				
1291	4717 H10	208	102% L1/1L4		227	148% B	4717:H10	#AD/B	OK	OK	OK	OK	OK				
							L2/L3	OK	OK	OK	OK	OK	OK				
							L1	L1	L1	L1	#AD/~B	OK	OK				

1292:4718:E11	212	104% L3/L4	180	118% B	4718:E11	OK	#AD/B	OK	OK	OK	OK
1293:4720:D2	205	100% AD/BI - No P, No Eggs	185	121% B	4720:D2	L3/L4	L3/L4	<	OK	OK	OK
1294:4720:D3	209	102% L1/L2	208	136% Dead(L4/AD)	4720:D3	L3/L4	L3/L4	L3/L4	OK	OK	OK
1295:4720:D8	212	104% L1/L2/Dead(L3/L4)	204	133% Dead(L4/AD)	4720:D8	L3/L4	L3/L4	L3/L4	#AD/BI	OK	OK
1296:4720:D10	202	99% Dead(L4)	212	139% Dead(AD)	4720:D10	L3/L4	L3/L4	L3/L4	#AD/BI	OK	OK
1297:4721:E1	220	108% L2	190	124% B - AD Husks	4721:E1	L3/L4	#AD/B	#AD/B	OK	OK	OK
1298:4721:E8	218	107% Dead/2L4	227	148% L2/L3	4721:E8	L2/L3	L3/L4	<	OK	OK	OK
1299:4721:E10	210	103% 5AD/B	206	135% B - Dying AD	4721:E10	L1/L2	#AD/B	#AD/B	OK	OK	OK
1300:4721:E11	209	102% L2/L3/1AD/BI	192	125% L4/AD/BI	4721:E11	B	#AD/B	OK	OK	OK	OK
1301:4722:F1	216	106% Dead	248	162% L3/L4/Dead(L4)	4722:F1	L1	L1/L4	#AD/BI	OK	OK	OK
1302:4723:D7	200	98% L1/L2/L3	203	133% BI - Dead (L4/AD)	4723:D7	Dead(L3)	L2/L3	#AD/B	<	OK	OK
1303:4724:E9	207	101% L3/L4/2AD/BI - No P, 1 B	212	139% Dead(L4/AD)	4724:E9	L1	L2/L3	#AD/B	OK	OK	OK
126:4724:E10	210	103% L2/L3/L4	220	144% L2/L3	4724:E10	L1/L2	L1/L2	L1/L2	#AD/BI	OK	OK
1304:4727:E4	224	110% L1/L2	218	142% BI - Dying	4727:E4	L1	#AD/B	OK	OK	OK	OK
1305:4727:A7	169	83% Dead	163	107% B	4727:A7	L1	L1	L1	OK	OK	OK
1306:4727:B7	187	92% Dead	195	127% L4/AD/BI	4727:B7	L1	#AD/BI	#AD/BI	OK	OK	OK
1307:4727:C7	186	91% Dead	207	135% 1AD/BI	4727:C7	L1	<	<	OK	OK	OK
1308:4727:D7	182	89% Dead	191	125% 5AD/BI	4727:D7	L1	#AD/B	<	OK	OK	OK
1309:4727:E7	192	94% Dead	202	132% 5AD/BI	4727:E7	L1	#AD/B	<	OK	OK	OK
1310:4727:F7	200	98% Dead	164	107% B	4727:F7	L1	<	<	OK	OK	OK
1311:4727:G7	201	99% Dead	169	110% L4/AD/BI	4727:G7	L1	#AD/BI	#AD/BI	OK	OK	OK
1312:4727:H7	215	105% Dead	157	103% B	4727:H7	BI	BI	BI	OK	OK	OK
102:4727:E8	224	110% L2/L3/1AD	211	138% B - AD Dying	4727:E8	Dead	#AD/B	#AD/B	OK	OK	OK
1313:4727:E9	215	105% L2/L3/1AD	204	133% B - AD Dying	4727:E9	L1/L2	L1/L2	L2/L3	L3	#AD/B	B
1314:4727:A10	176	86% L1	177	116% B	4727:A10	L1	L2/Dead(L	-B	OK	OK	OK
1315:4727:B10	184	90% L1	202	132% L3/L4/AD/BI	4727:B10	L1	<	OK	OK	OK	OK
1316:4727:C10	189	93% L1	157	103% B	4727:C10	L1	-B	OK	OK	OK	OK
1317:4727:D10	175	86% L1	196	128% 2L4/3AD/BI	4727:D10	L1	OK	OK	OK	OK	OK
1318:4727:E10	192	94% L1	172	112% B	4727:E10	L1	L1	L1	#AD/BI	OK	OK
1319:4727:F10	190	93% L1	206	135% L1/L2	4727:F10	L1	<	OK	OK	OK	OK
1320:4727:G10	194	95% L1	204	133% 2L4/1AD/BI	4727:G10	L1	#AD/B	OK	OK	OK	OK
1321:4727:H10	189	93% L1	205	134% B	4727:H10	L1	OK	OK	OK	OK	OK
1322:4728:C10	191	94% L1/L2	171	112% B	4728:C10	L1/L2	OK	OK	OK	OK	OK
1323:4728:D10	184	90% 1AD/BI	190	124% B	4728:D10	L1/L2	OK	OK	OK	OK	OK
1324:4729:D6	199	98% L1	189	124% 2AD/BI	4729:D6	L2/Dead(L3)	L4/#AD/BI	<	OK	OK	OK
1325:4729:E7	202	99% Dead	191	125% B	4729:E7	BI	BI	BI	OK	OK	OK

1326	4729	D10	186	91% L1	185	121% B	4729:D10	L1	OK	OK	OK	OK	OK
1327	4729	E10	192	94% L1	161	105% B	4729:E10	#AD/B	OK	OK	OK	OK	OK
1328	4739	D7	176	86% Dead	179	117% B	4739:D7	L1	<	OK	OK	OK	OK
1329	4739	E7	194	95% Dead	208	136% 4AD/B	4739:E7	L1	<	OK	OK	OK	OK
1330	4739	E9	200	98% Dead	156	102% 3AD/-B	4739:E9	L1	OK	OK	OK	OK	OK
1331	4739	E10	210	103% L2/L3	207	135% 5AD/B - Husks	4739:E10	L1/L2	OK	#AD/-B	OK	OK	OK
1332	4740	B7	192	94% Dead	189	124% 4AD/B	4740:B7	L1	L1	L1	~B	OK	OK
1333	4740	C7	192	94% Dead	160	105% B	4740:C7	L1	#AD/-B	OK	OK	OK	OK
1334	4740	D7	183	90% Dead	173	113% B	4740:D7	L1	<	OK	OK	OK	OK
1335	4740	F7	210	103% Dead	172	112% B	4740:F7	L1	<	OK	OK	OK	OK
1336	4740	G7	219	107% Dead	147	96% B	4740:G7	#AD/B!	B	OK	OK	OK	OK
1337	4740	G10	208	102% L1	202	132% B	4740:G10	L1	OK	OK	OK	OK	OK
1338	4741	D6	194	95% L1/L2	200	131% L2/L3	4741:D6	L1	OK	OK	OK	OK	OK
1339	4741	A7	165	81% Dead	181	118% 4AD/B	4741:A7	BI	BI	OK	OK	OK	OK
1340	4741	B7	188	92% Dead	165	108% B	4741:B7	L1	<	OK	OK	OK	OK
1341	4741	D7	193	95% Dead	176	115% B	4741:D7	#AD/B	OK	OK	OK	OK	OK
1342	4741	E7	195	96% Dead	209	137% 3AD/B!	4741:E7	L1	OK	OK	OK	OK	OK
1343	4741	F7	216	106% Dead	211	138% 1AD/B!	4741:F7	L1	<	OK	OK	OK	OK
1344	4741	H7	208	102% Dead	176	115% B	4741:H7	L1	OK	OK	OK	OK	OK
1345	4741	B10	192	94% 1AD/B!	159	104% B	4741:B10	#AD/B!	OK	OK	OK	OK	OK
1346	4741	D10	198	97% L1/L4	190	124% B - Dying AD	4741:D10	L1	L1	L1	OK	OK	OK
1347	4741	F10	205	100% Dead	182	119% B	4741:F10	OK	L3/L4	OK	OK	OK	OK
1348	4741	G10	208	102% Dead/1AD/B!	190	124% B	4741:G10	#AD/B!	OK	OK	OK	OK	OK
1349	4742	E11	218	107% L2/L3	221	144% L1/L2	4742:E11	#AD/B!	OK	OK	OK	OK	OK
1350	4744	D2	196	96% Dead	200	131% L4/Dead(L4/AD)	4744:D2	L2/Dead(L3)	L2/Dead(L3)	#AD/B	#AD/B	OK	OK
1351	4744	D3	208	102% L2/L3	192	125% B - AD Dying	4744:D3	Dead(L2/L3)	OK	OK	OK	OK	OK
1352	4744	D8	208	102% Dead	210	137% Dead(L3/L4)	4744:D8	L2/Dead(L3)	Dead(L3/LB)	OK	OK	OK	OK
1353	4744	D10	197	97% L2	203	133% Dead(L4/AD)	4744:D10	Dead(L2/L3)	BI	BI	OK	OK	OK
1354	4745	E1	220	108% L2/L3/L4	192	125% 4AD/B	4745:E1	Dead(L2/L3)	Dead(L3)	OK	OK	OK	OK
1355	4745	E10	210	103% L2/L3/L4	186	122% B	4745:E10	L1/L2	#AD/-B	OK	OK	OK	OK
1356	4746	F1	200	98% Dead	256	167% 4AD/B! - No P. AD	4746:F1	L2/L3	<	OK	OK	OK	OK
1357	4747	D1	203	100% Dead/2AD - Both Bag	174	114% 4AD/-B	4747:D1	L1	-B	OK	OK	OK	OK
1358	4747	D7	209	102% Dead	216	141% Dead(AD)	4747:D7	L3/Dead(AD)	<	OK	OK	OK	OK
1359	4747	D8	206	101% 1AD/B	164	107% 5AD/-B	4747:D8	Dead(L2/L3)	<	OK	OK	OK	OK
1360	4751	A7	159	78% Dead	174	138% 1AD/B!	4751:A7	L2/L3	OK	OK	OK	OK	OK
1361	4751	B7	188	92% 1AD/B	190	151% 1AD/B!	4751:B7	L1	L1	L1	L4#AD/B	OK	OK
								OK	#AD/-B	OK	OK	OK	OK
								L1	L1	OK	OK	OK	OK

1362	4751:C7	192	94%	Dead		199	158% L1/L2/L4	4751:C7	L1	#AD/~B	OK	OK	OK
1363	4751:D7	185	91%	Dead		194	154% L1/L2	4751:D7	L1	#AD/~B	OK	OK	OK
1364	4751:E7	192	94%	Dead		200	159% L1/L2	4751:E7	L1	#AD/B!	OK	OK	OK
1365	4751:F7	192	94%	Dead		209	166% 1AD/B!	4751:F7	L1	B	OK	OK	OK
1366	4751:G7	198	97%	Dead		191	152% L1/L2	4751:G7	L1	<	OK	OK	OK
1367	4751:H7	202	99%	Dead		184	146% 3AD/B	4751:H7	B!	B!	OK	OK	OK
1368	4751:B10	190	93%	Dead		175	139% 2AD/B	4751:B10	L1	OK	OK	OK	OK
1369	4751:C10	188	92%	2AD/B		174	138% B	4751:C10	L4#AD/B	OK	OK	OK	OK
1370	4752:B7	182	89%	Dead		193	153% L1/L2	4752:B7	#AD/B!	OK	OK	OK	OK
1371	4752:C7	191	94%	Dead		198	157% L1/L2	4752:C7	L1	#AD/B	~B	OK	OK
1372	4752:D7	187	92%	Dead		185	147% L2/L3	4752:D7	L1	#AD/B	OK	OK	OK
1373	4752:E7	197	97%	Dead		198	157% L1/L2	4752:E7	L1	~B	OK	OK	OK
1374	4752:F7	213	104%	Dead		202	160% L1/L2	4752:F7	L1	OK	OK	L1	#AD/~B
1375	4752:G7	200	98%	Dead		200	159% 1AD/B!	4752:G7	L1	#AD/B	<	OK	OK
1376	4752:H7	199	98%	Dead		208	165% L1/L2	4752:H7	L1	#AD/B	<	OK	OK
1377	4752:I10	197	97%	L2/L3		163	129% B	4752:I10	L1	B	OK	OK	OK
1378	4752:C10	195	96%	L1/L2		172	137% 4AD/B	4752:C10	#AD/B	OK	OK	OK	OK
1379	4752:E10	195	96%	1AD/B!		167	133% B	4752:E10	L1	OK	OK	OK	OK
1380	4752:F10	205	100%	Dead		179	142% B	4752:F10	L1/L2	OK	OK	OK	OK
1381	4752:H10	199	98%	2AD/B		209	166% L1/L2	4752:H10	L1	OK	OK	OK	OK
1382	4753:A7	168	82%	Dead		182	144% 1AD/B!	4753:A7	L1	OK	OK	OK	OK
1383	4753:B7	191	94%	Dead		191	152% 1AD/B!	4753:B7	L1	~B	OK	OK	OK
1384	4753:C7	187	92%	Dead		194	154% 1AD/B!	4753:C7	#AD/B	OK	OK	OK	OK
1385	4753:D7	196	96%	Dead		195	155% L1/L2	4753:D7	L1	#AD/B	OK	OK	OK
1386	4753:E7	194	95%	Dead		197	156% L1/L2	4753:E7	L1	#AD/B	OK	OK	OK
1387	4753:F7	182	89%	Dead		207	164% L1/L2	4753:F7	L1/L2	L4#AD/B!	#AD/~B	OK	OK
1388	4753:G7	177	87%	Dead		218	173% L1/L2	4753:G7	L1	#AD/B	OK	#AD/~B	OK
1389	4753:H7	189	93%	Dead		203	161% L1/L2	4753:H7	L1/L2	#AD/B	<	OK	OK
1390	4753:I10	188	92%	L1/L2		193	153% 5AD/B!	4753:I10	L1	OK	OK	OK	OK
1391	4753:D10	193	95%	Dead		177	140% 5AD/B	4753:D10	L4#AD/B!	OK	OK	OK	OK
1392	4753:E10	192	94%	Dead		202	160% L1/L2	4753:E10	L1/L2	OK	OK	OK	OK
1393	4753:F10	203	100%	Dead		212	168% L1/L2	4753:F10	L1/L2	OK	OK	OK	OK
1394	4753:H10	207	101%	L2/L3/L4		175	139% 5AD/B	4753:H10	L4#AD/B!	OK	OK	OK	OK
1395	4756:D8	260	127%	Dead		200	159% Dead(L4/AD)	4756:D8	B!	B!	OK	OK	OK
1396	4758:F1	197	97%	Dead		161	128% B! - No P. Healthy	4758:F1	Dead(L4)	Dead(L4)	OK	OK	OK
1397	4758:F2	224	110%	2AD/B!		157	125% B - Healthy, Unhalt	4758:F2	#AD/B!	OK	OK	OK	OK
1398	4758:F2	224	110%	2AD/B!		157	125% B - Healthy, Unhalt	4758:F2	L4#AD/B	OK	OK	OK	OK

1398	4763:A7	170	83% Dead	193	153% L1/L2	4763:A7	#AD/B	OK	OK	OK	OK	OK
1399	4763:B7	191	94% Dead	205	163% 1AD/B!	4763:B7	L1	<	OK	OK	OK	OK
1400	4763:C7	192	94% Dead	192	152% 1AD/B!	4763:C7	L1/L2	OK	OK	OK	OK	OK
1401	4763:D7	183	90% Dead	187	148% L1/L2	4763:D7	#AD/B!	<	OK	OK	OK	OK
1402	4763:E7	189	93% Dead	199	158% L1/L2	4763:E7	L1	L1	L1	#AD/B	OK	OK
1403	4763:F7	190	93% Dead	202	160% L1/L2	4763:F7	#AD/B!	OK	OK	OK	OK	OK
1404	4763:G7	201	99% Dead	193	153% 1AD/B!	4763:G7	L1	OK	OK	OK	OK	OK
1405	4763:H7	184	90% Dead	203	161% L1/L2	4763:H7	L1	<	OK	OK	OK	OK
1406	4763:A10	162	79% Dead	172	137% 2AD/B!	4763:A10	L1	OK	OK	OK	OK	OK
1407	4763:B10	173	85% Dead	190	151% L1/L2	4763:B10	L1	<	OK	OK	OK	OK
1408	4763:C10	191	94% Dead/2AD/B! - No P	195	155% L1/L2	4763:C10	L1	OK	OK	OK	OK	OK
1409	4763:D10	180	88% Dead	190	151% L1/L2	4763:D10	L1	OK	OK	OK	OK	OK
1410	4763:E10	183	90% Dead	199	158% L1/L2	4763:E10	L1	B	OK	OK	OK	OK
1411	4763:F10	193	95% Dead	199	158% L1/L2	4763:F10	L1	<	OK	OK	OK	<
1412	4763:G10	190	93% Dead	193	153% 3AD/B!	4763:G10	#AD/B!	<	OK	OK	OK	OK
1413	4763:H10	206	101% 1AD/B!	200	159% 1AD/B!	4763:H10	L1/L2	OK	OK	OK	OK	OK
1414	4764:A7	216	106% Dead	182	144% 1AD/B!	4764:A7	L1	<	OK	OK	OK	OK
1415	4764:B7	228	112% Dead	194	154% 2AD/B	4764:B7	L4#AD/B!	<	OK	OK	OK	OK
1416	4764:C7	234	115% Dead	195	155% 1AD/B	4764:C7	L4#AD/B!	L1	L1	OK	OK	OK
1417	4764:D7	227	111% Dead	187	148% 1AD/B!	4764:D7	#AD/B!	<	OK	OK	OK	OK
1418	4764:E7	240	118% Dead	195	155% 2AD/B!	4764:E7	#AD/B!	<	OK	OK	OK	OK
1419	4764:F7	243	119% 1AD/B!	203	161% L1/L2	4764:F7	L1	B	OK	OK	OK	OK
1420	4764:G7	236	116% Dead	178	141% L1/L2	4764:G7	L1/L2	<	OK	OK	OK	OK
1421	4764:H7	230	113% Dead	203	161% L1/L2	4764:H7	L1	OK	OK	OK	OK	OK
1422	4764:A10	200	98% Dead	182	144% L1/L2	4764:A10	L1	OK	OK	OK	OK	OK
1423	4764:B10	196	96% Dead	198	157% 1AD/B!	4764:B10	L1/L2	OK	OK	OK	OK	OK
1424	4764:C10	190	93% Dead	197	156% L1/L2	4764:C10	L1/L2	<	OK	OK	OK	OK
1425	4764:D10	196	96% Dead	193	153% L1/L2	4764:D10	L1/L2	<	OK	OK	OK	OK
1426	4764:F10	213	104% Dead	211	167% L1/L2	4764:F10	L1	<	OK	OK	OK	OK
1427	4764:G10	214	105% Dead	208	165% L1/L2	4764:G10	L1/L2	OK	OK	OK	OK	OK
1428	4764:H10	229	112% Dead	218	173% L2/L3	4764:H10	L1/L2	<	OK	OK	OK	OK
1429	4765:A7	175	86% Dead	181	144% 1AD/B!	4765:A7	#AD/B!	OK	OK	OK	OK	OK
1430	4765:B7	185	91% Dead	197	156% 1AD/B!	4765:B7	L1	L1	L1	L1	OK	OK
1431	4765:C7	195	96% Dead	198	157% L1/L2	4765:C7	L1	L4#AD/B	OK	OK	OK	OK
1432	4765:D7	187	92% Dead	192	152% L1/L2	4765:D7	L1	#AD/B	OK	OK	OK	OK
1433	4765:E7	190	93% Dead	201	160% 1AD/B!	4765:E7	L1	<	OK	OK	OK	<

1434: 4765 F7	190	93% Dead		193	153% 2AD/B!		4765:F7	#AD/B!	OK	OK	OK	OK	OK
1435: 4765 G7	192	94% Dead		195	155% L1/L2		4765:G7	L1	OK	OK	OK	OK	OK
1436: 4765 H7	203	100% Dead		199	158% L1/L2		4765:H7	L1/L2	B	<	OK	OK	OK
1437: 4765 A10	161	79% Dead		176	140% 4AD/B!		4765:A10	BI	B	BI	OK	OK	OK
1438: 4765 B10	165	81% Dead		196	156% 1AD/B!		4765:B10	L1	<	OK	OK	OK	OK
1439: 4765 C10	180	88% Dead		197	156% 2L4/2AD/B!		4765:C10	L1/L2	<	OK	OK	OK	OK
1440: 4765 D10	193	95% Dead		194	154% L1/L2		4765:D10	L1	OK	OK	OK	OK	OK
1441: 4765 E10	171	84% Dead		200	159% L1/L2		4765:E10	L1	#AD/B!	OK	OK	OK	OK
1442: 4765 F10	192	94% Dead		205	163% 1AD/B!		4765:F10	L1	~B	OK	OK	OK	OK
1443: 4765 G10	187	92% Dead		207	164% L1/L2		4765:G10	L1	OK	OK	OK	OK	OK
1444: 4765 H10	180	88% Dead		209	166% L1/L2		4765:H10	L1/L2	L1	L1	OK	OK	OK
1445: 4770 F1	203	100% Dead		201	160% BI - No P, Healthy,		4770:F1	L1	OK	OK	OK	OK	OK
1446: 4770 F8	222	109% L1/L2		172	137% B		4770:F8	L4/#AD/B!	~B	OK	OK	OK	OK
1447: 4775 A7	176	86% 1AD/B!		176	140% 1AD/B!		4775:A7	L1	OK	<	<	OK	OK
1448: 4775 C7	192	94% Dead		196	156% 1AD/B!		4775:C7	L1	~B	<	OK	OK	OK
1449: 4775 D7	184	90% Dead		188	149% 1AD/B!		4775:D7	L1	~B	OK	OK	OK	OK
1450: 4775 E7	196	96% Dead		203	161% L1/L2		4775:E7	L1	#AD/B	OK	OK	OK	OK
1451: 4775 F7	205	100% Dead		208	165% L1/L2		4775:F7	BI	BI	BI	OK	OK	OK
1452: 4775 G7	200	98% Dead		184	146% 2AD/B!		4775:G7	L1	OK	OK	OK	OK	OK
1453: 4775 H7	190	93% Dead		185	147% 1AD/B		4775:H7	L1	<	OK	OK	OK	OK
1454: 4775 E9	205	100% L1/L2		181	144% L4AD/B		4775:E9	#AD/B	OK	OK	OK	OK	OK
1455: 4775 A10	150	74% Dead		167	133% L1/L2		4775:A10	L1/L2	OK	OK	OK	OK	OK
1456: 4775 B10	173	85% Dead		183	145% L1/L2		4775:B10	L1	OK	OK	OK	OK	OK
1457: 4775 C10	178	87% 1AD/B!		183	145% L1/L2		4775:C10	L1	~B	OK	OK	OK	OK
1458: 4775 D10	172	84% Dead		180	143% L1/L2		4775:D10	L1	L1	L1	OK	OK	OK
1459: 4775 E10	171	84% Dead		190	151% L1/L2		4775:E10	L1	~B	OK	OK	OK	OK
1460: 4775 F10	188	92% Dead		196	156% L1/L2		4775:F10	L1	B	~B	OK	OK	OK
1461: 4775 G10	201	99% 1AD/B		181	144% 5AD/B		4775:G10	L1	OK	OK	OK	OK	OK
1462: 4776 A7	168	82% Dead		151	120% 3AD/~B		4776:A7	L1	OK	OK	OK	OK	OK
1463: 4776 B7	187	92% Dead		175	139% 4AD/B		4776:B7	L1	<	OK	OK	OK	OK
1464: 4776 C7	195	96% L1		179	142% 3AD/B		4776:C7	L1	OK	OK	OK	OK	OK
1465: 4776 D7	186	91% Dead		182	144% 2AD/B		4776:D7	BI	BI	BI	OK	OK	OK
1466: 4776 E7	190	93% 1AD/B		198	157% 1AD/B!		4776:E7	L1	~B	OK	OK	OK	OK
1467: 4776 F7	200	98% L1		182	144% 4AD/B		4776:F7	#AD/B	B	OK	OK	OK	OK
1468: 4776 G7	202	99% Dead		182	144% 1AD/B!		4776:G7	L1	OK	OK	OK	OK	OK
1469: 4776 A10	166	81% Dead		171	136% L1/L2		4776:A10	L1	<	<	OK	OK	OK

Example 8 – Sheep Test I Experimental Procedure

Sheep naturally infected with a variety of gastrointestinal nematodes are purchased from local sources and are transported to the test site. The animals are housed in a manner to preclude further infection by nematode larvae. The animals are evaluated
5 for the presence of adequate nematode burdens by performing a standard fecal egg per gram (EPG) count. Eggs are differentiated into the following groups: trichostrongyle (strongyle), Strongyloides, Trichuris, or Nematodinis. Only sheep judged by the study parasitologist to have adequate nematode infections are used retained as test subjects.

The sheep are fed good quality hay (no concentrated rations) and water ad
10 libitum. Following a five-day acclimation period, the sheep are randomly assigned by EPG count into treatment groups which include non-treated Negative control (placebo); Positive Control (commercially available ivermectin for sheep); and various anthelmintic compounds of the present invention (test compound) dissolved in DMSO. The first replicate of 10 animals is randomly assigned to groups 1-10; the second replicate of 10
15 animals is randomly assigned to groups 1-10; and the third replicate of 10 animals is randomly assigned to groups 1-10. Thus 10 groups of 3 animals each is created.

The randomization is performed on fecal samples collected 24-48 hours prior to scheduled treatment. The EPG counts are performed according to Zimmerman Research SOP # NMEPG.99.01

20 On treatment day, the animals are weighed and divided into groups with three animals per group as follows:

- GROUP 1: Non-treated negative control (placebo) of 10 ml of DMSO.
- GROUP 2: Positive Control treatment of 200 mcg/kg commercially available
25 ivermectin for sheep.
- GROUP 3: Compound @ dissolved in DMSO.
- GROUP 4: Compound @ dissolved in DMSO.
- GROUP 5: Compound @ dissolved in DMSO.
- GROUP 6: Compound @ dissolved in DMSO.
- 30 GROUP 7: Compound @ dissolved in DMSO.
- GROUP 8: Compound @ dissolved in DMSO.

GROUP 9: Compound @ dissolved in DMSO.

GROUP10: Compound @ dissolved in DMSO.

5 The placebo (DMSO), the commercially available drug, and the test anthelmintic compounds are administered in a 3ml volume by subcutaneous injection using a sterile syringe fitted with a proper needle. The animal is adequately immobilized for injection of the placebo, commercially available drug, or test anthelmintic compound.

Following treatment, the animals are observed at hourly intervals for the first 8 hours, then daily until necropsy. They will continue to be housed in a manner to prevent further nematode infections. Fecal samples are taken for EPG counts on the 5th 10 day and 7th day after treatment.

Seven days following treatment the sheep are humanely slaughtered in accordance with the Guide for the Care and Use of Laboratory Animals (DHEW Publication No. 86-23). Necropsy procedures are according to Zimmerman Research SOP # 15 NCRGIH.99.01, Necropsy for Helminth Recovery, specifically for gastrointestinal nematodes. Fecal samples are taken for EPG counts during the sample collection process on this day. All animals are necropsied, but only the animals from the experimental treatment groups that have a significant egg count reduction on day 5 or day 7 have intestinal material collected for nematode recovery and identification.

20 Nematodes are recovered, identified, and enumerated according to Zimmerman Research SOP # NEMRECOVID.99.01. All individuals performing nematode recoveries are blinded to treatment versus control animals. Preliminary estimates of total nematodes recovered from each gut sample are provided prior to identification and enumerations by the study parasitologist. At the discretion of the study parasitologist, seven days after the 25 drug administration fecal egg counts are performed and all animals showing 90% or better trichostrongylid egg reduction will be slaughtered using humane methods recommended by the AVMA. The neck blood vessels are severed and after the animal is completely exsanguinated, the abdomen is opened. The abomasum, the small and large intestines are tied at the omasal and pyloric openings, the duodenum, the end of the small 30 intestine and at the end of the large intestine. Each section is transferred in a separate bucket containing warm water and is slit open and thoroughly washed. The epithelium

is inspected before it is removed. The thus prepared washings are saved in gallon jars. An appropriate preservative is added. If preservative is not available, all the intestinal washing should kept in a refrigerator. These washings are passed through a 100-mesh sieve (pore size 149 μ m), and the residue is examined for the presence of worms under a dissecting microscope. Lugol's solution may be used to stain the worms. All worms are picked up counted and identified as to the species. An effort should be made to recover any immature forms present. The efficacy should be calculated using the controlled anthelmintic test.

$$\text{Percentage efficacy} = \frac{\begin{array}{c} \text{(Mean number of worms in controls minus} \\ \text{Mean number of worms in treated animal)} \end{array}}{\text{Mean number of worms in controls}} \times 100$$

Results are depicted in Tables 4 and 5.

Table 4

Akkadix	AKK 101	Sheep	Trial	17-Jan		
	Sheep	Weight/lbs	Injection	Worm	Counts	
	Number	1/17/2000	Abomasum	Abomasum	Small Intestine	Small Intest.
			Haemonchus	Ostertagia	Trichostrongylus	Nematodirus
Group	81	84	420	60	0	140
Negative	75	116	500	860	320	2300
Control	56	87	0	0	80	0
Mean Ct.			307	307	133	813
Group	83	98	0	0	0	0
Ivermectin	92	129	0	0	0	0
200mcg/kg	53	82	0	0	0	0
Mean Ct.			0	0	0	0
		%Efficacy	100	100	100	100
Group	58	74	0	80	380	1660
AKC 102	71	51	20	2440	3720	180
1.4mg/kg	60	107	0	0	480	280
Mean Ct.			7	840	1527	707
		%Efficacy	98			

Table 5

Akkadix	Trial -1	Sheep	AKK 101	Strongyles	Strongyles		Strongyles	
	Sheep	Weight/lbs	Total	17-Jan	22-Jan		24-Jan	
	Number	1/12/2000	EPG-pre	EPG-pre	EPG-5day	% Change	EPG-7day	%Change
Group 1	58	73	4690	4640	300		260	94.40
AKC 102	71	48	1670	1630	310		NS	80.98
1.4mg/kg	60	100	310	40	10		0	100.00
Total / Mean		221	2223.33	2103.33	206.67	90.17	86.67	95.88
Group 2	83	91	2310	2000	10		0	100.00
Ivermectin	92	113	570	570	0		0	100.00
.2mg/kg	53	77	90	70	0		0	100.00
Total / Mean		281	990.00	880.00	3.33	99.62	0.00	100.00
Group 3	81	74	2240	2240	780		770	65.63
Negative	75	109	370	300	260		1360	-353.33
Control	56	80	40	40	30		30	25.00
Total / Mean		263	883.33	860.00	356.67	58.53	720.00	16.28

Example 9 – Sheep Test II Experimental Procedure

Sheep naturally infected with a variety of gastrointestinal nematodes are purchased from local sources and are transported to the test site. The animals are housed in a manner to preclude further infection by nematode larvae. The animals are evaluated
5 for the presence of adequate nematode burdens by performing a standard fecal egg per gram (EPG) count. Eggs are differentiated into the following groups: trichostrongyle (strongyle), Strongyloides, Trichuris, or Nematodirus. Only sheep judged by the study parasitologist to have adequate nematode infections are retained as test subjects.

The sheep are fed good quality hay (no concentrated rations) and water ad
10 libitum. Following a five day acclimation period, the sheep are randomly assigned by EPG count into the following treatment groups: Groups 1-9, various anthelmintic compounds of the present invention (test compound) dissolved in DMSO: Group 10, Positive Control (commercially available ivermectin for sheep); Group 11, non-treated Negative control (DMSO only). The first replicate of 11 animals is randomly assigned
15 to groups 1-11; the second replicate of 11 animals is randomly assigned to groups 1-11; and the third replicate of 11 animals is randomly assigned to groups 1-11. Thus 11 groups of 3 animals each are created.

The randomization is performed on fecal samples collected 24-48 hours prior to scheduled treatment. The EPG counts are performed according to Zimmerman Research
20 SOP # NMEPG.99.01.

- GROUP 1: AKKADIX compound dissolved in DMSO.
- GROUP 2: AKKADIX compound dissolved in DMSO.
- GROUP 3: AKKADIX compound dissolved in DMSO.
- 25 GROUP 4: AKKADIX compound dissolved in DMSO.
- GROUP 5: AKKADIX compound dissolved in DMSO.
- GROUP 6: AKKADIX compound dissolved in DMSO.
- GROUP 7: AKKADIX compound dissolved in DMSO.
- GROUP 8: AKKADIX compound dissolved in DMSO.
- 30 GROUP 9: AKKADIX compound dissolved in DMSO.
- GROUP 10: Positive Control treatment of 200 mcg/kg commercially available

ivermectin for sheep.

GROUP11: Non-treated negative control (placebo) of 3 ml of DMSO.

On treatment day, the animals are weighed, tagged, and divided into groups of
5 three animals per group as follows:

The placebo (DMSO), the commercially available drug, and the test anthelmintic
compounds are administered in a 3ml volume of DMSO by subcutaneous injection using
a sterile syringe fitted with a sterile needle. The site of injection is clipped and swabbed
with alcohol prior to injection. The animal is adequately immobilized for injection of the
10 placebo, commercially available drug, or experimental compound.

Following treatment, the animals are observed at hourly intervals for the first 8
hours, then daily until necropsy. They are housed in a manner to prevent further
nematode infections.

On the fifth day following treatment, fecal samples are obtained from each
15 animal, properly labeled and used for EPG counts.

Seven days following treatment, all the sheep are weighed and humanely
slaughtered in accordance with the Guide for the Care and Use of Laboratory Animals
(DHEW Publication No. 86-23). Necropsy procedures are according to Zimmerman
Research SOP # NCRGIH.00.01, Necropsy for Helminth Recovery, specifically for
20 gastrointestinal nematodes. Fecal samples are taken for EPG counts during the sample
collection process on this day.

Nematodes are recovered, identified, and enumerated according to Zimmerman
Research SOP # NEMRECOVID.00.01. All individuals performing nematode recoveries
are blinded to treatment versus control animals.

25

Anthelmintic efficacy is calculated using the controlled test procedure:

$$\% \text{ Efficacy} = \frac{\text{Mean number of worms in controls minus mean number of worms in treated}}{\text{Mean number of worms in controls}} \times 100$$

5

Results are depicted in Tables 6 and 7.

Table 6

Akkadix	AKK-102	Sheep	24-May				
	Sheep	Weight/lbs		Worm	Counts		
	Number	5/17/2000	Abomasum	Abomasum	Small Intestine	Small Intest.	Large Intest.
			Haemonchus	Ostertagia	Trichostrongylus	Nematodirus	Trichuris
Group	530	47	60	580	40	8500	5
Negative	1341	57	60	20	20	2520	15
Control	524	54	20	80	0	0	10
Mean Ct.			47	227	20	3673	10
Group	1347	45	0	0	0	100	0
Ivermectin	1336	58	20	0	0	100	0
200mcg/kg	539	47	0	0	0	0	0
Mean Ct.			7	0	0	67	0
		%Efficacy	86	100	100	98	
Group	1348	45	20	340			
AKC 102	1332	42	160	1380			
1mg/kg	1338	33	0	100			
Mean Ct.			60	607			
		%Efficacy	-29				

Table 7

Akkadix	Trial -2	Sheep	AKK 102	Strongyles	Strongyles		Strongyles	
	Sheep	Weight/lbs	Total	15-May	22-May		24-May	
	Number	5/17/2000	EPG-pre	EPG-pre	EPG-5day	% Change	EPG-7day	%Change
Group	1348	45	760	110	120		420	-281.82
AKC 102	1332	42	350	270	2332		570	-111.11
1mg/kg	1338	33	100	70	30		70	0.00
Total / Mean		120	403.33	150.00	827.33	-451.56	353.33	-135.56
Group	530	47	710	640	690		300	53.13
Negative	1341	57	160	120	160		340	-183.33
Control	524	54	70	60	140		50	16.67
Total / Mean		158	313.33	273.33	330.00	-20.73	230.00	15.85
Group 10	1334	41	560	530	690		290	45.28
AKC 110	536	40	280	220	850		1510	-586.36
3.5mg/kg	1339	46	70	40	0		30	25.00
Total / Mean		127	303.33	263.33	513.33	-94.94	610.00	-131.65
Group	1347	45	560	450	0		0	100.00
Ivermectin	1336	58	220	170	0		0	100.00
200mcg/kg	539	47	100	40	0		0	100.00
Total / Mean		150	293.33	220.00	0.00	100.00	0.00	100.00

It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.

Claims

What is claimed is:

- 1 1. A method for controlling nematodes which comprises contacting said
2 nematodes with a nematode-controlling effective amount of a composition comprising
3 at least one compound having Structure 47.
- 1 2. A method for controlling nematodes which comprises contacting said
2 nematodes with a nematode-controlling effective amount of a composition comprising
3 at least one compound having a structure selected from the group consisting of Structures
4 48-290.
- 1 3. The method of claim 2, wherein said compound is Compound 48.
- 1 4. The method of claim 2, wherein said compound is Compound 49.
- 1 5. The method of claim 2, wherein said compound is Compound 50.
- 1 6. The method of claim 2, wherein said compound is Compound 51.
- 1 7. The method of claim 2, wherein said compound is Compound 52.
- 1 8. The method of claim 2, wherein said compound is Compound 53.
- 1 9. The method of claim 2, wherein said compound is Compound 54.
- 1 10. The method of claim 2, wherein said compound is Compound 55.
- 1 11. The method of claim 2, wherein said compound is Compound 56.
- 1 12. The method of claim 2, wherein said compound is Compound 57.

- 1 13. The method of claim 2, wherein said compound is Compound 58.
- 1 14. The method of claim 2, wherein said compound is Compound 59.
- 1 15. The method of claim 2, wherein said compound is Compound 60.
- 1 16. The method of claim 2, wherein said compound is Compound 61.
- 1 17. The method of claim 2, wherein said compound is Compound 62.
- 1 18. The method of claim 2, wherein said compound is Compound 63.
- 1 19. The method of claim 2, wherein said compound is Compound 64.
- 1 20. The method of claim 2, wherein said compound is Compound 65.
- 1 21. The method of claim 2, wherein said compound is Compound 66.
- 1 22. The method of claim 2, wherein said compound is Compound 67.
- 1 23. The method of claim 2, wherein said compound is Compound 68.
- 1 24. The method of claim 2, wherein said compound is Compound 69.
- 1 25. The method of claim 2, wherein said compound is Compound 70.
- 1 26. The method of claim 2, wherein said compound is Compound 71.
- 1 27. The method of claim 2, wherein said compound is Compound 72.

- 1 28. The method of claim 2, wherein said compound is Compound 73.
- 1 29. The method of claim 2, wherein said compound is Compound 74.
- 1 30. The method of claim 2, wherein said compound is Compound 75.
- 1 31. The method of claim 2, wherein said compound is Compound 76.
- 1 32. The method of claim 2, wherein said compound is Compound 77.
- 1 33. The method of claim 2, wherein said compound is Compound 78.
- 1 34. The method of claim 2, wherein said compound is Compound 79.
- 1 35. The method of claim 2, wherein said compound is Compound 80.
- 1 36. The method of claim 2, wherein said compound is Compound 81.
- 1 37. The method of claim 2, wherein said compound is Compound 82.
- 1 38. The method of claim 2, wherein said compound is Compound 83.
- 1 39. The method of claim 2, wherein said compound is Compound 84.
- 1 40. The method of claim 2, wherein said compound is Compound 85.
- 1 41. The method of claim 2, wherein said compound is Compound 86.
- 1 42. The method of claim 2, wherein said compound is Compound 87.
- 1 43. The method of claim 2, wherein said compound is Compound 88.

- 1 44. The method of claim 2, wherein said compound is Compound 89.
- 1 45. The method of claim 2, wherein said compound is Compound 90.
- 1 46. The method of claim 2, wherein said compound is Compound 91.
- 1 47. The method of claim 2, wherein said compound is Compound 92.
- 1 48. The method of claim 2, wherein said compound is Compound 93.
- 1 49. The method of claim 2, wherein said compound is Compound 94.
- 1 50. The method of claim 2, wherein said compound is Compound 95.
- 1 51. The method of claim 2, wherein said compound is Compound 96.
- 1 52. The method of claim 2, wherein said compound is Compound 97.
- 1 53. The method of claim 2, wherein said compound is Compound 98.
- 1 54. The method of claim 2, wherein said compound is Compound 99.
- 1 55. The method of claim 2, wherein said compound is Compound 100.
- 1 56. The method of claim 2, wherein said compound is Compound 101.
- 1 57. The method of claim 2, wherein said compound is Compound 102.
- 1 58. The method of claim 2, wherein said compound is Compound 103.

- 1 59. The method of claim 2, wherein said compound is Compound 104.
- 1 60. The method of claim 2, wherein said compound is Compound 105.
- 1 61. The method of claim 2, wherein said compound is Compound 106.
- 1 62. The method of claim 2, wherein said compound is Compound 107.
- 1 63. The method of claim 2, wherein said compound is Compound 108.
- 1 64. The method of claim 2, wherein said compound is Compound 109.
- 1 65. The method of claim 2, wherein said compound is Compound 110.
- 1 66. The method of claim 2, wherein said compound is Compound 111.
- 1 67. The method of claim 2, wherein said compound is Compound 112.
- 1 68. The method of claim 2, wherein said compound is Compound 113.
- 1 69. The method of claim 2, wherein said compound is Compound 114.
- 1 70. The method of claim 2, wherein said compound is Compound 115.
- 1 71. The method of claim 2, wherein said compound is Compound 116.
- 1 72. The method of claim 2, wherein said compound is Compound 117.
- 1 73. The method of claim 2, wherein said compound is Compound 118.
- 1 74. The method of claim 2, wherein said compound is Compound 119.

1 75. The method of claim 2, wherein said compound is Compound 120.

1 76. The method of claim 2, wherein said compound is Compound 121.

1 77. The method of claim 2, wherein said compound is Compound 122.

1 78. The method of claim 2, wherein said compound is Compound 123.

1 79. The method of claim 2, wherein said compound is Compound 124.

1 80. The method of claim 2, wherein said compound is Compound 125.

1 81. The method of claim 2, wherein said compound is Compound 126.

1 82. The method of claim 2, wherein said compound is Compound 127.

1 83. The method of claim 2, wherein said compound is Compound 128.

1 84. The method of claim 2, wherein said compound is Compound 129.

1 85. The method of claim 2, wherein said compound is Compound 130.

1 86. The method of claim 2, wherein said compound is Compound 131.

1 87. The method of claim 2, wherein said compound is Compound 132.

1 88. The method of claim 2, wherein said compound is Compound 133.

1 89. The method of claim 2, wherein said compound is Compound 134.

1 90. The method of claim 2, wherein said compound is Compound 135.

1 91. The method of claim 2, wherein said compound is Compound 136.

1 92. The method of claim 2, wherein said compound is Compound 137.

1 93. The method of claim 2, wherein said compound is Compound 138.

1 94. The method of claim 2, wherein said compound is Compound 139.

1 95. The method of claim 2, wherein said compound is Compound 140.

1 96. The method of claim 2, wherein said compound is Compound 141.

1 97. The method of claim 2, wherein said compound is Compound 142.

1 98. The method of claim 2, wherein said compound is Compound 143.

1 99. The method of claim 2, wherein said compound is Compound 144.

1 100. The method of claim 2, wherein said compound is Compound 145.

1 101. The method of claim 2, wherein said compound is Compound 146.

1 102. The method of claim 2, wherein said compound is Compound 147.

1 103. The method of claim 2, wherein said compound is Compound 148.

1 104. The method of claim 2, wherein said compound is Compound 149.

1 105. The method of claim 2, wherein said compound is Compound 150.

- 1 106. The method of claim 2, wherein said compound is Compound 151.
- 1 107. The method of claim 2, wherein said compound is Compound 152.
- 1 108. The method of claim 2, wherein said compound is Compound 153.
- 1 109. The method of claim 2, wherein said compound is Compound 154.
- 1 110. The method of claim 2, wherein said compound is Compound 155.
- 1 111. The method of claim 2, wherein said compound is Compound 156.
- 1 112. The method of claim 2, wherein said compound is Compound 157.
- 1 113. The method of claim 2, wherein said compound is Compound 158.
- 1 114. The method of claim 2, wherein said compound is Compound 159.
- 1 115. The method of claim 2, wherein said compound is Compound 160.
- 1 116. The method of claim 2, wherein said compound is Compound 161.
- 1 117. The method of claim 2, wherein said compound is Compound 162.
- 1 118. The method of claim 2, wherein said compound is Compound 163.
- 1 119. The method of claim 2, wherein said compound is Compound 164.
- 1 120. The method of claim 2, wherein said compound is Compound 165.

- 1 121. The method of claim 2, wherein said compound is Compound 166.
- 1 122. The method of claim 2, wherein said compound is Compound 167.
- 1 123. The method of claim 2, wherein said compound is Compound 168.
- 1 124. The method of claim 2, wherein said compound is Compound 169.
- 1 125. The method of claim 2, wherein said compound is Compound 170.
- 1 126. The method of claim 2, wherein said compound is Compound 171.
- 1 127. The method of claim 2, wherein said compound is Compound 172.
- 1 128. The method of claim 2, wherein said compound is Compound 173.
- 1 129. The method of claim 2, wherein said compound is Compound 174.
- 1 130. The method of claim 2, wherein said compound is Compound 175.
- 1 131. The method of claim 2, wherein said compound is Compound 176.
- 1 132. The method of claim 2, wherein said compound is Compound 177.
- 1 133. The method of claim 2, wherein said compound is Compound 178.
- 1 134. The method of claim 2, wherein said compound is Compound 179.
- 1 135. The method of claim 2, wherein said compound is Compound 180.
- 1 136. The method of claim 2, wherein said compound is Compound 181.

- 1 137. The method of claim 2, wherein said compound is Compound 182.
- 1 138. The method of claim 2, wherein said compound is Compound 183.
- 1 139. The method of claim 2, wherein said compound is Compound 184.
- 1 140. The method of claim 2, wherein said compound is Compound 185.
- 1 141. The method of claim 2, wherein said compound is Compound 186.
- 1 142. The method of claim 2, wherein said compound is Compound 187.
- 1 143. The method of claim 2, wherein said compound is Compound 188.
- 1 144. The method of claim 2, wherein said compound is Compound 189.
- 1 145. The method of claim 2, wherein said compound is Compound 190.
- 1 146. The method of claim 2, wherein said compound is Compound 191.
- 1 147. The method of claim 2, wherein said compound is Compound 192.
- 1 148. The method of claim 2, wherein said compound is Compound 193.
- 1 149. The method of claim 2, wherein said compound is Compound 194.
- 1 150. The method of claim 2, wherein said compound is Compound 195.
- 1 151. The method of claim 2, wherein said compound is Compound 196.

1 152. The method of claim 2, wherein said compound is Compound 197.

1 153. The method of claim 2, wherein said compound is Compound 198.

1 154. The method of claim 2, wherein said compound is Compound 199.

1 155. The method of claim 2, wherein said compound is Compound 200.

1 156. The method of claim 2, wherein said compound is Compound 201.

1 157. The method of claim 2, wherein said compound is Compound 202.

1 158. The method of claim 2, wherein said compound is Compound 203.

1 159. The method of claim 2, wherein said compound is Compound 204.

1 160. The method of claim 2, wherein said compound is Compound 205.

1 161. The method of claim 2, wherein said compound is Compound 206.

1 162. The method of claim 2, wherein said compound is Compound 207.

1 163. The method of claim 2, wherein said compound is Compound 208.

1 164. The method of claim 2, wherein said compound is Compound 209.

1 165. The method of claim 2, wherein said compound is Compound 210.

1 166. The method of claim 2, wherein said compound is Compound 211.

1 167. The method of claim 2, wherein said compound is Compound 212.

- 1 168. The method of claim 2, wherein said compound is Compound 213.
- 1 169. The method of claim 2, wherein said compound is Compound 214.
- 1 170. The method of claim 2, wherein said compound is Compound 215.
- 1 171. The method of claim 2, wherein said compound is Compound 216.
- 1 172. The method of claim 2, wherein said compound is Compound 217.
- 1 173. The method of claim 2, wherein said compound is Compound 218.
- 1 174. The method of claim 2, wherein said compound is Compound 219.
- 1 175. The method of claim 2, wherein said compound is Compound 220.
- 1 176. The method of claim 2, wherein said compound is Compound 221.
- 1 177. The method of claim 2, wherein said compound is Compound 222.
- 1 178. The method of claim 2, wherein said compound is Compound 223.
- 1 179. The method of claim 2, wherein said compound is Compound 224.
- 1 180. The method of claim 2, wherein said compound is Compound 225.
- 1 181. The method of claim 2, wherein said compound is Compound 226.
- 1 182. The method of claim 2, wherein said compound is Compound 227.

- 1 183. The method of claim 2, wherein said compound is Compound 228.
- 1 184. The method of claim 2, wherein said compound is Compound 229.
- 1 185. The method of claim 2, wherein said compound is Compound 230.
- 1 186. The method of claim 2, wherein said compound is Compound 231.
- 1 187. The method of claim 2, wherein said compound is Compound 232.
- 1 188. The method of claim 2, wherein said compound is Compound 233.
- 1 189. The method of claim 2, wherein said compound is Compound 234.
- 1 190. The method of claim 2, wherein said compound is Compound 235.
- 1 191. The method of claim 2, wherein said compound is Compound 236.
- 1 192. The method of claim 2, wherein said compound is Compound 237.
- 1 193. The method of claim 2, wherein said compound is Compound 238.
- 1 194. The method of claim 2, wherein said compound is Compound 239.
- 1 195. The method of claim 2, wherein said compound is Compound 240.
- 1 196. The method of claim 2, wherein said compound is Compound 241.
- 1 197. The method of claim 2, wherein said compound is Compound 242.
- 1 198. The method of claim 2, wherein said compound is Compound 243.

- 1 199. The method of claim 2, wherein said compound is Compound 244.
- 1 200. The method of claim 2, wherein said compound is Compound 245.
- 1 201. The method of claim 2, wherein said compound is Compound 246.
- 1 202. The method of claim 2, wherein said compound is Compound 247.
- 1 203. The method of claim 2, wherein said compound is Compound 248.
- 1 204. The method of claim 2, wherein said compound is Compound 249.
- 1 205. The method of claim 2, wherein said compound is Compound 250.
- 1 206. The method of claim 2, wherein said compound is Compound 251.
- 1 207. The method of claim 2, wherein said compound is Compound 252.
- 1 208. The method of claim 2, wherein said compound is Compound 253.
- 1 209. The method of claim 2, wherein said compound is Compound 254.
- 1 210. The method of claim 2, wherein said compound is Compound 255.
- 1 211. The method of claim 2, wherein said compound is Compound 256.
- 1 212. The method of claim 2, wherein said compound is Compound 257.
- 1 213. The method of claim 2, wherein said compound is Compound 258.

- 1 214. The method of claim 2, wherein said compound is Compound 259.
- 1 215. The method of claim 2, wherein said compound is Compound 260.
- 1 216. The method of claim 2, wherein said compound is Compound 261.
- 1 217. The method of claim 2, wherein said compound is Compound 262.
- 1 218. The method of claim 2, wherein said compound is Compound 263.
- 1 219. The method of claim 2, wherein said compound is Compound 264.
- 1 220. The method of claim 2, wherein said compound is Compound 265.
- 1 221. The method of claim 2, wherein said compound is Compound 266.
- 1 222. The method of claim 2, wherein said compound is Compound 267.
- 1 223. The method of claim 2, wherein said compound is Compound 268.
- 1 224. The method of claim 2, wherein said compound is Compound 269.
- 1 225. The method of claim 2, wherein said compound is Compound 270.
- 1 226. The method of claim 2, wherein said compound is Compound 271.
- 1 227. The method of claim 2, wherein said compound is Compound 272.
- 1 228. The method of claim 2, wherein said compound is Compound 273.
- 1 229. The method of claim 2, wherein said compound is Compound 274.

2 230. The method of claim 2, wherein said compound is Compound 275.

1 231. The method of claim 2, wherein said compound is Compound 276.

1 232. The method of claim 2, wherein said compound is Compound 277.

1 233. The method of claim 2, wherein said compound is Compound 278.

1 234. The method of claim 2, wherein said compound is Compound 279.

1 235. The method of claim 2, wherein said compound is Compound 280.

1 236. The method of claim 2, wherein said compound is Compound 281.

1 237. The method of claim 2, wherein said compound is Compound 282.

1 238. The method of claim 2, wherein said compound is Compound 283.

1 239. The method of claim 2, wherein said compound is Compound 284.

1 240. The method of claim 2, wherein said compound is Compound 285.

1 241. The method of claim 2, wherein said compound is Compound 286.

1 242. The method of claim 2, wherein said compound is Compound 287.

1 243. The method of claim 2, wherein said compound is Compound 288.

1 244. The method of claim 2, wherein said compound is Compound 289.

1 245. The method of claim 2, wherein said compound is Compound 290.

1/99

FIG. 1




FIG. 2




FIG. 3





FIG. 4



2/99

FIG. 5




FIG. 6




FIG. 7





FIG. 8



3/99

FIG. 9




FIG. 10




FIG. 11





FIG. 12



4/99

FIG. 13




FIG. 14




FIG. 15





FIG. 16



5/99

FIG. 17




FIG. 18




FIG. 19





FIG. 20



6/99

FIG. 21




FIG. 22





FIG. 23



7/99

FIG. 24




FIG. 25




FIG. 26





FIG. 27



8/99

FIG. 28




FIG. 29




FIG. 30





FIG. 31



9/99

FIG. 32




FIG. 33




FIG. 34





FIG. 35



10/99

FIG. 36




FIG. 37




FIG. 38




FIG. 39




FIG. 40




FIG. 41




FIG. 42




FIG. 43




FIG. 44




FIG. 45





FIG. 46



12/99

FIG. 47




FIG. 48




FIG. 49





FIG. 50



SUBSTITUTE SHEET (RULE 26)

13/99

FIG. 51




FIG. 52





FIG. 53



14/99

FIG. 54




FIG. 55





FIG. 56



15/99

FIG. 57




FIG. 58




FIG. 59





FIG. 60



16/99

FIG. 61




FIG. 62





FIG. 63



17/99

FIG. 64




FIG. 65





FIG. 66



18/99

FIG. 67




FIG. 68





FIG. 69



SUBSTITUTE SHEET (RULE 26)

19/99

FIG. 70




FIG. 71





FIG. 72



20/99

FIG. 73




FIG. 74





FIG. 75



SUBSTITUTE SHEET (RULE 26)

FIG. 76




FIG. 77





FIG. 78



22/99

FIG. 79




FIG. 80





FIG. 81



SUBSTITUTE SHEET (RULE 26)

23/99

FIG. 82




FIG. 83





FIG. 84



24/99

FIG. 85




FIG. 86





FIG. 87



25/99

FIG. 88




FIG. 89





FIG. 90



SUBSTITUTE SHEET (RULE 26)

26/99

FIG. 91





FIG. 92



27/99

FIG. 93





FIG. 94



28/99

FIG. 95




FIG. 96





FIG. 97



SUBSTITUTE SHEET (RULE 26)

29/99

FIG. 98





FIG. 99



30/99

FIG. 100




FIG. 101





FIG. 102



31/99

FIG. 103




FIG. 104





FIG. 105



32/99

FIG. 106




FIG. 107





FIG. 108



33/99

FIG. 109




FIG. 110





FIG. 111



34/99

FIG. 112




FIG. 113





FIG. 114



35/99

FIG. 115




FIG. 116





FIG. 117



36/99

FIG. 118




FIG. 119





FIG. 120



37/99

FIG. 121




FIG. 122





FIG. 123







FIG. 125



39/99

FIG. 126





FIG. 127



40/99

FIG. 128





FIG. 129



41/99

FIG. 130




FIG. 131





FIG. 132



42/99

FIG. 133




FIG. 134





FIG. 135



43/99

FIG. 136





FIG. 137



44/99

FIG. 138




FIG. 139





FIG. 140



45/99

FIG. 141




FIG. 142





FIG. 143



46/99

FIG. 144




FIG. 145





FIG. 146



47/99

FIG. 147




FIG. 148





FIG. 149



48/99

FIG. 150




FIG. 151





FIG. 152



49/99

FIG. 153




FIG. 154





FIG. 155



50/99

FIG. 156




FIG. 157





FIG. 158



51/99

FIG. 159




FIG. 160





FIG. 161



52/99

FIG. 162




FIG. 163





FIG. 164



53/99

FIG. 165




FIG. 166





FIG. 167



54/99.

FIG. 168




FIG. 169





FIG. 170



55/99

FIG. 171




FIG. 172





FIG. 173



56/99

FIG. 174




FIG. 175





FIG. 176



57/99

FIG. 177




FIG. 178





FIG. 179



58/99

FIG. 180




FIG. 181




FIG. 182




FIG. 183




FIG. 184





FIG. 185



60/99

FIG. 186




FIG. 187





FIG. 188



61/99

FIG. 189




FIG. 190





FIG. 191



62/99

FIG. 192




FIG. 193





FIG. 194



63/99

FIG. 195




FIG. 196





FIG. 197



64/99

FIG. 198




FIG. 199





FIG. 200



65/99

FIG. 201




FIG. 202





FIG. 203



66/99

FIG. 204




FIG. 205





FIG. 206



67/99

FIG. 207




FIG. 208





FIG. 209



68/99

FIG. 210




FIG. 211





FIG. 212



69/99

FIG. 213




FIG. 214





FIG. 215



70/99

FIG. 216





FIG. 217



71/99

FIG. 218





FIG. 219



72/99

FIG. 220




FIG. 221





FIG. 222



73/99

FIG. 223




FIG. 224





FIG. 225



74/99

FIG. 226




FIG. 227





FIG. 228



75/99

FIG. 229




FIG. 230





FIG. 231



76/99

FIG. 232




FIG. 233





FIG. 234



77/99

FIG. 235




FIG. 236





FIG. 237



78/99

FIG. 238




FIG. 239





FIG. 240



79/99

FIG. 241




FIG. 242





FIG. 243



80/99

FIG. 244




FIG. 245





FIG. 246



81/99

FIG. 247




FIG. 248





FIG. 249



82/99

FIG. 250




FIG. 251





FIG. 252



83/99

FIG. 253




FIG. 254





FIG. 255



84/99

FIG. 256




FIG. 257





FIG. 258



85/99

FIG. 259




FIG. 260





FIG. 261



86/99

FIG. 262




FIG. 263




FIG. 264




FIG. 265




FIG. 266





FIG. 267



88/99

FIG. 268




FIG. 269





FIG. 270



89/99

FIG. 271




FIG. 272




FIG. 273




FIG. 274




FIG. 275





FIG. 276



91/99

FIG. 277




FIG. 278





FIG. 279



92/99

FIG. 280




FIG. 281




FIG. 282




FIG. 283

93/99




FIG. 284





FIG. 285



94/99

FIG. 286




FIG. 287





FIG. 288



95/99

FIG. 289






FIG. 290








FIG. 292




FIG. 293




FIG. 294




FIG. 295




FIG. 296




FIG. 297

98/99




FIG. 298




FIG. 299

99/99





FIG. 300



Modified Idea

Original Idea

FIG. 301

INTERNATIONAL SEARCH REPORT

In national Application No

PCT/US. 01/02871

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A01N37/36 A01N41/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 171 355 A (BERTRAM HEINZ-JUERGEN ET AL) 15 December 1992 (1992-12-15) claims	1
A	WO 92 15555 A (MONSANTO CO) 17 September 1992 (1992-09-17) page 2, line 1 -page 4, line 19 compound 54 compound 125	1



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

30 March 2001

Date of mailing of the international search report

16/05/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Donovan-Beermann, T

INTERNATIONAL SEARCH REPORT

Int. Patent Application No
PCT/US 01/02871

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1982 LIANG Y-Y ET AL: "AUTO RADIOGRAPHIC STUDY ON TISSUE LOCALIZATION OF CARBON-14 LABELED CUCURBITINE IN MICE" Database accession no. PREV198376062994 XP002164312 abstract & ACTA PHARMACOLOGICA SINICA, vol. 3, no. 4, 1982, pages 267-269, ISSN: 0253-9756 abstract</p> <p>-----</p>	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. ...nal Application No

PCT/US 01/02871

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5171355	A	15-12-1992	DE 4029054 A	19-03-1992
			DE 59106761 D	30-11-1995
			EP 0475236 A	18-03-1992
			JP 4288053 A	13-10-1992
			US 5254696 A	19-10-1993
			US 5256795 A	26-10-1993
<hr/>				
WO 9215555	A	17-09-1992	AT 172957 T	15-11-1998
			AU 664031 B	02-11-1995
			AU 1556992 A	06-10-1992
			BG 61505 B	31-10-1997
			BG 98084 A	27-05-1994
			BR 9205711 A	17-05-1994
			CA 2104005 A	02-09-1992
			CN 1064479 A, B	16-09-1992
			CN 1269136 A	11-10-2000
			CZ 9301779 A	13-04-1994
			DE 69227527 D	10-12-1998
			DE 69227527 T	24-06-1999
			DK 640069 T	19-07-1999
			EP 0640069 A	01-03-1995
			EP 0798285 A	01-10-1997
			ES 2123553 T	16-01-1999
			GR 3029297 T	28-05-1999
			HU 65415 A	28-06-1994
			IE 920647 A	09-09-1992
			JP 6505485 T	23-06-1994
			KR 132120 B	13-04-1998
			MX 9200875 A	01-09-1992
			NZ 241796 A	28-03-1995
			PL 167415 B	30-09-1995
			PT 100177 A, B	31-05-1993
			RO 112854 B	30-01-1998
			RU 2117658 C	20-08-1998
			SK 92993 A	09-03-1994
			TR 26646 A	15-03-1995
			US 5389680 A	14-02-1995
			US 5457134 A	10-10-1995
			US 5561162 A	01-10-1996
			US 5623084 A	22-04-1997
			US 5714517 A	03-02-1998
			US 5693865 A	02-12-1997
			ZA 9201535 A	30-12-1992
			ZW 3092 A	13-05-1992

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINE(S) OR MARK(S) ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.